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1. 
INThODUCTION. 
" BEIuch of the medical research of recent generations, 
especially in Britain, has lost much, and in some cases 
all, of its value from failure to confirm the facts upon 
which it is founded; it has wasted time and effort in 
proving or disproving theories which were not serious and 
in explaining phenomena which had not been proved to 
exist." (1)'' 
The above generalisation, from a leading article in 
one of last year's journals, is particularly applicable 
to a goodly portion of the work that has been done on the 
relationship between vitamin C and infectious diseases. 
The view that in fevers there is an increased need for 
vitamin C has gained wide currency, and has even been 
stated dogmatically in an editorial in 'The Lancet' (2); 
yet a mere glance at the steadily accumulating mass of 
literature on the subject reveals that some workers seek 
to bring about a state of hypervitaminosis, some wish to 
remedy a hypovitaminosis which they regard as important 
in the causation of the illness, some maintain that the 
hypovitaminosis is simply a result of either increased 
metabolism or reduced intake, and a few deny the very 
existance of any hypovitaminosis. Even a casual survey, 
too, makes it obvious that some of the conclusions of 
early workers in the field were based on methods which 
have since been proved faulty, or on arbitrary and Quite 
unjustified standards, and that these invalid conclusions 
have sometimes been accepted by later researchers as a 
stable basis for their own work. 
In these circumstances a comprehensive investigation 
of the effects of ascorbic acid therapy in infectious 
diseases seems very desirable. 
Part 2 of this thesis is a humble attempt at such an 
investigation in a few selected diseases, the method 
employed consisting of a comparative study of patients 
treated with vitamin C and controls suffering from the 
same diseases; and Part 1 is a brief critical review of 
the relevant literature. 
PART / 
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2. 
PART 1 - REVIEW OF THE LITERATURE. 
It is convenient to divide previous investigations 
of the relationship between vitamin C and infectious 
diseases into three groups: first, those concerned with 
determining the effects of infectious conditions on the 
bodily stores of the vitamin, i.e.,the evidence for and 
against the existence of hypovitaminosis C in patients 
suffering from zymotic diseases; second, anti -bacterial 
effects of ascorbic acid in vitro, and experiments on 
laboratory animals; and, third, effects of administration 
of the vitamin to infectious patients. 
The first of these three divisions presupposes the 
existence both of methods of estimating the vitamin and 
of standards of normality. Since the employment of an 
inaccurate method of estimation, or the comparison of 
correct estimates of the vitamin C levels of infectious 
patients with false standards of normality, might well 
lead to the formation of erroneous conclusions regarding 
the presence or absence of hypovitaminosis C, it seems 
desirable that the methods of assessing the nutritional 
status in respect of vitamin C and the various standards 
of normality should also be considered. 
The following critical summary of previous work is 
therefore divided into five sections: 
(1) Vitamin C, - methods of assay and normal standards; 
(2) Application of these standards to infections; 
(3) Effects of ascorbic acid in vitro, and experiments 
on laboratory animals; 
(4) Effects of administration of vitamin C to infectious 
patients; and 
(5) Other points of interest. 
(1) VITAÌiMIN C, - METHODS OF ASSAY, AND NORMAL STANDARDS. 
The methods of estimating vitamin C include tests of 
capillary fragility, quantitative estimation of the 
urinary excretion, "Saturation" tests, an intradermal 
test, and quantitative estimations of the concentration 
in blood or plasma. 
(A) Capillary Fragility Tests. 
A method of estimating vitamin C nutrition by placing 
a pressure cuff round the arm for a specified time and then 
counting the number of petechiae that developed in an area 
of standard size was originated by Hess (3) in 1914, and 
modifications were introduced by Gothlin (4), Dalldorf and 
Russell/ 
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hussell (5), Schultz (6), and Brown and Wasson (7). Some 
lack of relationship between cuff test results and vitamin 
C was noted by many workers - e.g. Greene (8), O'Hara and 
Hauch (9), van .Eekelen (10), and Farmer (11); and cases were 
reported of actual scurvy in which the capillary fragility 
was within normal limits (12 & 13); but it fell to the man 
who had originally isolated vitamin C, Szent- Gyorgyi, to 
discover (14) that the permeability of capillaries was 
controlled, not by vitamin C, but by a previously unknown 
substance which the Hungarian scientist named, " Vitamin P." 
The final coin de grace to the cuff test as a measure of 
vitamin C nutrition was dealt by Scarborough (15), who 
proved conclusively that ascorbic acid does not decrease 
capillary fragility, whereas a Hesperidin preparation (i.e. 
Szent- Gyorgyi's Vitamin P ) does so very dramatically. 
Capillary fragility tests have been extensively used, 
even after the .discovery of vitamin F. For instance, in 
1942 they were employed by kunro, Lazarus, and Bell (12) 
in the expectation that they would be " the most sensitive 
index of the state of nutrition in regard to vitamin C "; 
and, a little earlier, they were used by Boje (16) in his 
investigation of the prevalence of hypovitaminosis C in 
Greenland. 
Since capillary fragility is definitely not an index 
of the state of ascorbic acid nutrition, it follows that 
on cuff tests are invalid. 
The first standards for the necessary daily intake 
of vitamin C were formulated by Gothlin (4) in 1931; he 
found that 21 - 30 mg. were required to " prevent undue 
capillary fragility "; and in 1937, on the basis of his 
previous findings, together with certain data from some 
animal experiments, he estimated (17) that an average 
adult required 19 - 27 mg. of ascorbic acid daily. These 
standards, based on an invalid test, have no significance; 
yet, as Godber (18) has pointed out in a brilliant thesis 
( which will be discussed later in some detail ), they 
have been made the basis for some subsequent estimates of 
human requirements of ascorbic acid. 
(B) ,Quantitative Estimates of Vitamin C in Urine. 
A quantitative test for vitamin C, based on the 
principle that the blue dye, 2:6 dichlorophenol- indophenol, 
is, in acid solution, reduced from a pink to a colourless 
liquid by ascorbic acid, was devised by Tillmans (19) as 
early as 1932, and elaborated by Abbasy et alii (20). The 
dye test is already sufficiently well known to be included 
in standard text -books on biochemistry (21), and need not, 
therefore, be described here. 
One or two modifications have been suggested, - e.g. 
Hess / 
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Hess and Benjamin (25) used the dye test but preserved the 
urine with trichioroacetic acid, instead of with glacial 
acetic; lancou, Oprisiu and Jula (26) advised some changes 
in the technique; and Harrison (22) suggested regenerating 
oxidised ascorbic acid with H2S prior to titration. None 
of these modifications, however, has passed into popular 
use. Again, several alternative tests have been devised: 
the methods of Evelyn (27) and Bessay (28), both involving 
the use of a photo- electric colorimeter, are fairly specific 
but unsuitable for general use; that of Iv:edes (29 6c 30 ), 
titrating with phospho- 18- tungstic acid, was claimed by the 
authoress to be more accurate for urines rich in ascorbic 
acid, but is too complicated for general clinical work; and 
that of hoe and Hall (31), using a 2:4 dinitrophenylhydrazine 
derivative of dehydroascorbic acid, does not appear to have 
any great advantage over the original dye test. Prior to 
1941, then, the dichlorophenol -indophenol test stood 
virtually unchallenged. 
In 1941, G. T. I:íeiklejohn and C. F. Stewart devised 
an entirely new test for ascorbic acid. Their method, 
based on the fact that cucumber seeds contain an active 
enzyme that oxidises vitamin C, is fairly simple, involves 
no elaborate apparatus, and - unlike previous methods - 
is absolutely specific for ascorbic acid. Hence it is 
likely to become the method of choice in the future. 
However, the enzyme test is still comparatively new. 
Practically all the work on the excretion of vitamin C 
has been done with the dichlorophenol - indophenol test, the 
accuracy of which must now be considered. 
The objection that it is seldom convenient to titrate 
every specimen of urine immediately it is voided, and that 
in stored urine a portion of the ascorbic acid is lost by 
oxidation, carries little weight; for, if the urine is 
stored under proper conditions ( in darkness, in stoppered 
bottles containing glacial acetic acid, etc. ) the amount 
of ascorbic acid lost over a period of twelve hours is only 
about ten per cent of the total; moreover, as the proportion 
so lost is fairly constant, the loss by oxidation should 
not, so long as the same test is employed, interfere with 
the compilation of standards of normality or the decision 
as to whether any particular patient has a low excretion 
of ascorbic acid. 
IL:ore important, however, is the argument that 2:6 
dichlorophenol - indophenol is reduced by certain other 
constituents of urine. Starting with Hopkins and Morgan 
(33), a number of workers have shown that the dye is 
reduced by such substances as glutathione, ergothionine, 
cystine and thiosulphate, of which the last two are normal 
constituents of urine. The original advocates of the dye 
test (20) claimed that the amount of non -specific reduction 
is equivalent to a maximum of 3 - 6 mg. out of a total of 
20 mg./ 
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20 mg. daily for a normal adult, and that such low values 
will not materially affect the comparison of results; but 
a consideration of the variations in the urinary excretion 
of cystine and thiosulphate hardly substantiates these 
claims. For cystine, Looney (34), using his calorimetric 
method, estimated the output of normal persons at 0 - 10 
mg. per 100 cc. of urine (i.e. 0 - 150 mg. daily ), and 
kedes (35), employing a different method, calculated that 
the normal limits for the daily excretion of cystine were 
between 1 and 84 mg.; moreover, in addition to normal 
individuals, with their very wide variations of excretion, 
there is also a rare - and frequently " missed" - disease 
of cystinuria, in which the daily output of cystine may 
be as much as 500 mg. (24), or about 33 mg./ 100 cc. urine. 
As for thiosulphate, the urinary excretion of this subst- 
ance depends on the amount of protein eaten: consequently 
a high protein diet may cause an increased decolorisation 
of the dye (36 & 37). 
These points militate against the specificity of the 
dichlorophenol- indophenol test as applied to apparently 
healthy persons, and help to explain why such workers as 
Ingalls (38), Hawley et alii (39), van Eekelen (10),Youmans 
and others (40), Parsons (41), and Wright and his co- workers 
(42) have found such marked variation in the excretion of 
individuals on the same diet, and even in the excretion of 
the same person at different times, although Wright's sug- 
-gestion that the differences are due to individual 
variations in the absorption of vitamin C is by no means 
to be lightly discarded. These points may also afford a 
clue to the hitherto unsolved riddle of why some cases of 
frank scurvy appeared to excrete up to 20 mg. of ascorbic 
acid daily. (22). 
Even if the dye test be deemed sufficiently specific 
for application to healthy persons, any attempt to apply 
it to disease raises further possible fallacies: patients 
suffering from diseases commonly receive drugs, and we do 
not yet know all the drugs which affect the excretion of 
ascorbic acid. We do know, however, that if the urinary 
pH is raised by giving sodium bicarbonate the excretion 
of vitamin C is reduced ( possibly through destruction of 
the vitamin in the alkaline bladder ), whilst a reduction 
of the pH by the administration of ammonium chloride 
increases the excretion of the vitamin (43 & 44 ); and 
that treatment with salicylates, including aspirin, also 
raises the output of vitamin C.(45). 
The dye test, with its many fallacies, is only a 
very approximate indication of the actual level of vitamin 
C excretion. Hence standards of " Normality " and of 
" health " based solely on this test are unlikely to be 
particularly accurate. Of the various " Normals " and 
" standards " that have been laid down, a few may be ment- 
ioned as examples: Harris and others (46), using a rather 
inadeouate/ 
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inadequate number of patients, assessed the normal daily 
concentration of vitamin C in urine at 0.03 mg. per cc., 
or for an average adult a total excretion of about 45 mg. 
daily; Harris and hay (47), after careful investigation, 
concluded that a urinary concentration above .01 - .02 mg. 
per cc. implied adequate nutrition in respect of ascorbic 
acid, or, in terms of total excretion, that an adult whose 
daily output was above 15 - 30 mg. could be regarded as 
free from any hypovitaminosis C; Abbasy and his co- workers 
(20) suggested that the minimum daily excretion for a 
healthy adult should be 10 mg.; and Toverud (48) found 
that the average excretion of adult females was about 37 
mg. per day. 
These standards of very limited and partial accuracy 
are mentioned here only because - as will be shown later 
- certain conclusions regarding the excretion of vitamin 
C in infectious diseases have been based solely on the dye 
test. 
(C) Saturation Tests. 
The principle of giving a test dose of a substance 
and investigating its fate is well known in medicine, - 
e.g. the laevulose tolerance test for hepatic efficiency. 
Applying this principle to ascorbic acid, numerous workers 
have enabled us to form a clear idea of the general trend 
of results: when a large dose of vitamin C is given to an 
individual who is already well nourished in respect of the 
vitamin, he at once responds by an increased excretion of 
that substance; in other words, his tissues are more or 
less saturated, so that much of the test dose has to be 
excreted. On the other hand, poor nutrition in respect 
of the vitmrnin is revealed by the absence of any marked 
increase in the excretion; the tissues are not nearly sat- 
-urated, and for a few days they absorb most of the addit- 
-ional ascorbic acid administered. 
Whilst the general picture is clear, the questions of 
the optimum dosage for the test and of the exact interpret- 
ation of results are still controversial. 
The original propounders of the saturation test ( 46, 
47 & 20 ) advocated an oral dose of 700 - 1,000 mg. of the 
vitamin daily. They said that all subjects free from 
hypovitaminosis respond by an abrupt rise in excretion, 
whereas " unsaturated " persons retain the excess vitamin 
C to remedy the unsaturation; and they further claimed 
that the point of demarcation lies in the vicinity of a 
pre- dosage excretion of 13 mg. per day. Using this test 
in conjunction with the ones previously mentioned, Harris 
and others (49) attempted to devise standards for the 
intake and output of the vitamin. They fed six adults on 
a diet containing little or no vitamin C until their reser- 
ves were very low, and then gave 25 mg. of the vitamin 
daily; the excretion rose steadily for six or seven weeks 
to/ 
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to 13 - 14.8 mg., and at this point all six gave " good 
responses " to a test dose of 700 mg. In a subsequent 
experiment they gave 40 mg. per day, and after five weeks 
the excretion became stabilised at 25 - 29 mg. " On the 
basis of this work, an excretion of 13 mg. daily, for an 
average adult of ten stone weight, has been described as 
the minimum standard excretion. " (18) 
For these suggested standards there is really very 
little evidence. The intake of 25 mg. daily was based 
mainly on Gothlin's "reputed minimum optimal dose" (50), 
which - being itself based on the wholly invalid test of 
capillary fragility - is valueless. The standard of 
above 13 mg. for the excretion has been criticised by 
Godber (1g) on the ground that it merely indicates a 
state of saturation and that there is no evidence that 
unsaturation is incompatible with health. It might also 
be criticised on the ground that, since Harris accepted 
as satisfactory an excretion of 50% of the test dose, the 
"good responses" to a test dose, by individuals who were 
previously excreting 13 - 15 mg. per day, may indicate a 
considerable degree of unsaturation: and a degree of 
unsaturation so great that nearly half of the test dose 
is retained by the tissues may well be below the minimum 
compatible with perfect health. Hence these suggested 
standards - an intake of 25 mg. and an output of 13 mg.- 
may be either too high or too low. Iioreover, these 
standards were constructed from a grossly inadequate 
number of cases, - six in all; and the investigator who 
originally claimed ( in 1935 ) that 25 mg. represented 
the minimum adequate daily intake maintains in 1942 that 
over 30 mg. are necesEary. (57) 
Archer and Graham (51 & 52 ) regarded an excretion 
of half the test dose as unsatisfactory. Accordingly, 
they suggested a test which involved calculating the total 
amount of ascorbic acid given before the subject began to 
excrete 750 of his daily intake of 1,000 or 400 mg. On 
the other hand, Parsons (41) advocated the use of a higher 
test dose, with an excretion of l0¡ß regarded as indicating 
saturation. 
Ralli and his co- workers (53) and Finkle (54) pointed 
out that results from oral test doses might be partially 
vitiated by individual differences in degree of absorption. 
They therefore advised an intravenous test dose of 100 mg. 
Wright and others (42) accepted the principle of an intra- 
-venous test dose, but preferred to give 1,000 mg. 
Probably the technique most commonly used today is 
Harris's modification of his original method: a daily test 
dose of 70 mg. per stone of body weight is given, the 
vitamin C content of urine voided four to six hours after 
each dose ( i.e. at the time of the peak of the excretory 
response ) is estimated by titration of dichlorophenol- 
indophenol/ 
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indophenol, and the degree of unsaturation is measured 
by counting the number of days before the curve of 
excretion rises to a plateau. Harris, who showed in 
1940 (55) that, as the curve of excretion rises very 
steeply, the exact figure taken for the lower limit of 
saturation does not matter greatly, has recently claimed 
(56) that for persons with a high intake of vitamin C 
saturation is completed on the first day of dosing, for 
persons with just sufficient vitamin C in their diet the 
plateau is reached on the second day, failure to reach 
the plateau until the third day or later indicates 
deficiency of the vitamin, and in fully developed scurvy 
saturation is not completed for 7 - 10 days. In a 
subsequent article (57) he states, - 
"In my experience, an intake not greatly in 
excess of the League of Nations marginal standard 
( 30 mg.) will suffice to keep the organism at 
such a level that saturation, as already defined, 
is reached on the second day of test -dosing." 
Among the many workers who have used saturation tests 
may be mentioned Abbasy, Harris, and their colleagues (58, 
59, 60 & 61 ), Jetter and Bumbalo (62), Gander and 
Niederberger (63), Emmerie and van Eekelen (64), van 
Eekelen and Heinemann (65), Widenbauer (66), Scarborough 
and Stewart (67), Guggenheim (68), and Francis and Wormall 
(69). 
(v) Urinary Estimations and Saturation Tests - Conclusions. 
If the figures given separately by Medes and Looney 
for the excretion of cystine are correct, the ordinary dye 
test for the amount of ascorbic acid in the urine can be 
of but little value; and even if we accept Harris's claim 
that the non - specific reduction never amounts to more than 
6 mg. per day, such non - specific reduction is enough to 
give a very erroneous idea of the vitamin C excretion. It 
might, for example, make a man whose real output was only 
twelve milligrammes appear to be excreting half as much 
again. Also, the collection and storage of all the urine 
passed is no easy matter: to say nothing of the loss of 
defaecation urine, an ambulant patient may visit the 
lavatory unnoticed, an ill patient may be slightly incon- 
-tinent, or a nurse may inadvertently expose the stored 
urine to light or ( by failure to replace the stopper ) to 
air; any such event may reduce the apparent excretion by, 
say, 25 ;,. The alternative method of estimating merely 
the concentration of a single specimen has the disadvantage 
that the concentration cannot be relied on to remain 
stationary during the entire day. N:oreover, an already 
wide margin of error is made even wider by the fact that 
the excretion of vitamin C varies with the pH of the urine. 
The ordinary urine test, then, is a very rough approxim- 
-ation of limited value. 
The/ 
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The saturation tests, on the other hand, are fairly 
accurate: when we are dealing with a dramatic rise in the 
excretion of vitamin C ( e.g. from a pre- dosage level of 
20 mg. to a height of 200 mg.) a non - specific reduction 
accounting for a few milligrammes becomes of negligible 
importance; moreover, as was shown on page 7, we do not 
need to collect the entire day's output of urine, since 
the concentration at the period of maximal response is 
all that is required. 
The great difficulty with the saturation tests is 
that, since administration of vitamin C may have a thera- 
-peutic effect, they cannot be used in the initial 
construction of standards. For example, prodromal 
symptoms of scurvy have been noted since the days of 
Admiral Sir John Hawkins ( who described them in 1569), 
but, if we are confronted with a case that resembles a 
prodromal scurvy, we cannot use a saturation method to 
ascertain what extent of hypovitaminosis C exists in 
prodromal scurvy, because the ascorbic acid would prevent 
the scurvy from developing, and so leave us uncertain 
whether our suspect had really been a case of pre -clinical 
scurvy. 
Once definite standards are laid down, saturation 
tests are of real value; but in the past conclusions from 
such tests have sometimes been based on arbitrary and 
unjustified standards. 
(E) The Intradermal Test. 
hotter (70), Portnoy and Wilkinson (71) and others 
have used an intradermal test for the estimation of 
nutritional status in respect of vitamin C. A sterile 
solution is prepared, containing 2 mg. of 2:6 dichlorophenol 
- indophenol dissolved in 4.9 cc. of distilled water; from 
a finely graduated syringe .01 cc. of the solution is 
injected intradermally, raising a wheal of about 2 mm. 
diameter; and the time required for the complete disap- 
-pearance of the blue colour is noted. The proof that 
the disappearance of the colour is due to reduction of the 
dye, not to mere absorption from the area, is supplied by 
the fact that on intradermal injection of other dyes ( e.g. 
methylene blue) no similar decolorisation occurs. 
It is difficult to inject exactly 0.01 cc., but error 
from this source is minimised by injecting approximately 
0.01 cc. into four separate spots or the patient's arm and 
taking the average time required for the disappearance of 
the colour. 
Portnoy and Wilkinson, who found that the results of 
the intradermal test correlated well with blood estimations, 
claimed/ 
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claimed that " Individuals who are on a 'good' diet with 
regard to the vitamin give decolorisation times of 
of less than ten minutes, while those taking large 
amounts of vitamin C in their food give decoloris- 
ation times below five minutes.. On the other 
hand, prolongation of the decolorisation time over 
ten minutes is suggestive of a lack of vitamin C 
in the tissues. " (72) 
Although certain other workers (73) have contended 
that the test was unsatisfactory, it appears to give a 
reasonably accurate indication of the general state of the 
body in respect of ascorbic acid. However, as it has not 
been used in investigations of infectious patients, the 
intradermal test need not be further considered- 
21 Quantitative Estimates of Vitamin C in Plasma and 
Blood. 
Despite the relative popularity of urine tests, it is 
obvious that questions of urinary excretion and of renal 
threshold are not fundamental: what really matters is the 
nutritional state of the tissues. Hence examination of 
the blood should be the most direct and reliable method of 
determining vitamin C requirements and standards. 
As early as 1934 van Eekelen and others (74) devised, 
for the estimation of plasma ascorbic acid, a method which 
involved preliminary precipitation of the proteins with 
trichloroacetic acid. This method, however, was later 
superceded by the method of Farmer and Abt (75), which, as 
originally described, involves the preparation of a tungstic 
acid, protein -free filtrate, and titration of this with a 
solution of dichlorobenzone -indophenol: 5 cc. of blood are 
withdrawn from a vein, oxalated, and centrifuged; the 
supernatant plasma is pipetted into a large centrifuge tube, 
to which there are added 4 cc. of distilled water, 2 cc. of 
5% sodium tungstate, and - after thorough mixing of the 
previous contents - 2 cc. of one third normal sulphuric 
acid; after standing for two minutes the tube is centrifuged, 
and a clear fluid obtained; the fluid is then immediately 
titrated against a previously standardised solution of sodium 
2:6 dichlorobenzone -indophenol. This method gives the 
reduced ascorbic acid content of the plasma. 
A method of estimating the vitamin C content of whole 
blood was devised by kirsky and his co- workers (76): 5 cc. 
of oxalated blood and 5 cc. of 10jß trichloroacetic acid are 
mixed, and added to 5 cc. of N/6 mercuric acetate; .23 Gm. 
of calcium carbonate are added and the mixture is stirred 
thoroughly; the solution is then centrifuged, and a clear 
fluid obtained; to regenerate reduced ascorbic acid, H2S is 
bubbled through, and excess of that gas is removed with 
nitrogen; finally the clear fluid is titrated against 
dichlorophenol - indophenol/ 
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dichlorophenol-indophenol. 
A modified technique for the estimation of vitamin 
C in plasma was suggested by.Fijoan and Klemperer (77). 
An alternative method for whole blood was devised by Lund 
and others (78), employing methylene blue as an indicator. 
And Goth (79) used a saturation test: he determined the 
plasma level of ascorbic acid before, and two hours after, 
an intravenous injection of 300 mg. of the vitamin; and he 
claimed that, if the second concentration was found to be 
less than twice the first, a state of hypovitaminosis C 
existed. 
From the work of these investigators and of others 
who have studied the ascorbic acid content of blood or of 
plasma - e.g. Abt and Farmer (80) some three years after 
their original description of their method, Bajardi and 
Largulius (81), Faulkner and Taylor (82), Rhinehart and 
others (83), Wortis and his co- workers (84), Goldsmith 
and Ellinger (85), etc. - two main points emerge:- 
(a) There appears to be no real difference between 
plasma concentration and concentration in blood; in other 
words, the vitamin is evenly distributed between the 
plasma and the corpuscles. 
(b) From the very considerable amount of published 
work it should be possible to derive definite standards 
for the amount of ascorbic acid in human blood. 
Before the standards for the level of vitamin C in 
blood and plasma are considered, it should be noted that 
there are two possible fallacies in the plasma tests: a 
low plasma concentration of ascorbic acid may occur in a 
person who has adequate reserves in his tissues, purely 
as an immediate result of a reduction in his intake of the 
vitamin ( e.g. a febrile patient receiving a milk diet 
with little vitamin C ); and a high plasma concentration, 
while usually indicating an adequate store in the tissues, 
might be merely an immediate and temporary response to a 
large dose of the vitamin. 
jG) Levels of Ascorbic Acid in Blood and Plasma. 
The fallacies of the direct urine test and the impos- 
sibility of constructing initial standards from the satur- 
-ation test were demonstrated in an earlier section; and 
any lingering feeling that the dye test of urinary excretion 
could indicate the general state of the body in regard to 
vitamin C should be dispelled by the findings of Abt, Farmer 
and Epstein (11), and of van Eekelen (10): the first named 
group of workers showed that, while the amount of vitamin 
C in the plasma is closely correlated with the intake, there 
is no correlation between the concentrations of the vitamin 
in the plasma and in the urine; and van Eekelen, maintaining 
a/ 
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a young adult an a diet devoid of vitamin C for 83 days, 
found that, although the plasma concentration fell quite 
steadily from 1.7 mg. /100 cc. to 0.19 mg., the urinary 
excretion fell only from 13 mg. daily to 7 mg. ( In other 
words, either the dye test was inaccurate or the patient 
had no renal threshold for the vitamin). 
In the blood ascorbic acid is approximately evenly 
distributed between the plasma and the corpuscles (86). 
In investigating the different "Normal" findings of 
various workers, we have to remember that the results can 
be expressed in three ways: (a) the vitamin C content of 
whole blood can be ascertained and expressed as mg. /100 cc. 
of blood; (b) the vitamin C content of plasma can be 
calculated and expressed as mg. /100 cc. of plasma, - giving 
a figure similar to that of (a); and (c) the vitamin C 
content of plasma can be ascertained and expressed as mg./ 
100 cc. of the blood from which the plasma was derived, - 
giving a figure about half of that in (a) and (b). A 
hypothetical example will make this clear:- 100 cc. of 
blood contain approximately 50 cc. of plasma (87); if the 
50 cc. of corpuscles contain 0.5 mg. of vitamin C and the 
50 cc. of plasma contain 0.5 mg. of the vitamin, then it 
can be said (a) that the concentration of vitamin C in the 
blood is 1 mg. /100 cc. blood, or (b) that the concentration 
in the plasma is 1 mg. /100 cc. plasma, or (c) that the 
concentration in the plasma is 0.5 mg./ 100 cc. of blood. 
This point of terminology has to be watched. 
Broadly speaking, most workers have found that the 
average ascorbic acid content of blood or plasma - expressed 
as in (a) or (b), above, not as in (c) - is about 0.5 - 0.7 
mg. /100 cc., with fairly wide individual variations: thus 
Rhinehart and others (88) calculated that the plasma levels 
of medical students, a well nourished section of the com- 
-munity, varied between 0.25 and 1.45 mg. /100 cc., with the 
average about 0.75 mg.; Abt and his colleagues (11), 
investigating young adults, found that all their cases fell 
between 0.109 and 0.735 mg. /100 cc., but in a subsequent 
experiment (75) they calculated that the plasma range of 
concentrations in normal people was much higher, namely, 
from 0.687 to 2.29 mg. /100 cc.; Portnoy and Wilkinson (72) 
regarded 0.6 to 1.85 mg. /100 cc. as normal, and figures of 
below 0.45 mg. as indicating a dangerous depletion of the 
body stores; Schroeder (89) took 1 mg. /100 cc. as the normal 
blood level ( and 50 mg. as the minimum daily intake ); 
Ingalls (38) tried to formulate standards of plasma vitamin 
C thus - Saturation, 2. - 1. mg. /100 cc. 
Optimum Normal, 1. - .7 " " 
Low, .7 - .5 " " 
Suboptimum - - - - .5 - .3 " " 
Asymptomatic scurvy, .3 - .15 " 
Scurvy, .15- 0 " it 
Eddy and Balldorf (90), in an authoritative exposition, said 
" In our experience blood assay has yielded values of nearly 
1 mg./ 
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1 mg. per cent in the vast majority of adults "; and a 
leading article in the 'British Ledical Journal' of 14th. 
February, 1942, quotes Linot's figure (91) of 0.7 mg. per 
100 cc. of plasma as the minimum concentration indicating 
a satisfactory nutritional state in respect of vitamin C. 
Standing foursquare against all these findings are 
the anomalous results of Fox and his co- workers. (73). 
For seven months they investigated two parallel groups of 
natives employed in one of the gold mines of the Witwater- 
- srand, each group consisting of 950 individuals. Group 
A received the " usual diet ", containing about 15 -25 mg. 
of ascorbic acid daily, whilst Group B received an addit- 
-ional daily ration of 40 mg. of vitamin C per person, in 
the form of an orange -juice concentrate. In Group A 12 
persons developed scurvy, as compared with only one case 
in Group B, but no significant difference was found between 
the groups in regard to general condition, gain or loss of 
weight, working efficiency, susceptibility to infections 
( e.g. influenza, pneumonia, vaticella, and tuberculosis ), 
or rate of healing of wounds and fractures. The ascorbic 
acid content of the plasma was estimated in 74 healthy 
members of Group A, 86 similar members of Group 13, and 17 
cases of scurvy ( including a few not in the original 
experiment ). Fox and his colleagues record the levels 
of plasma vitamin C in mg. per 100 cc. blood: to avoid 
confusion ( see page 11 ) their figures are therefore here 
into the more usual terminology. Their findings 
may be summarised thus: - 
Vitamin C in mg. /100 cc of plasma. 
Average. Range. 
74 controls ( after 0.46 mg. 0.30 - 0.80. 
seven months) 
86 men given extra 0.504 mg. 0.28 - 0.96. 
vitamin C (after 
seven months) 
17 cases of scurvy 0.348 mg. 0.20 - 1.0. 
Also, the capillary fragility test was negative in every 
patient tested, Dalldorf's method being the one employed; 
and trotter's intradermal test gave practically no differ - 
-ences between test cases, healthy controls, and cases of 
scurvy. 
From these results Fox and his co- workers conclude 
that the daily vitamin C requirement of native mine lab- 
-ourers, even when engaged in strenuous physical exercise, 
is very small indeed, and that " A net daily intake of 
about 15 mg. of ascorbic acid, perhaps even less, can 
evidently protect the majority of such individuals from 
scurvy." They would, presumably, also maintain that a 
plasma concentration of 0.46 mg. /100 cc. is shown to be 
compatible with health. 
After a detailed study of their paper, the present 
writer is disposed to draw very different conclusions: - 
The 950 controls received a diet containing 15 - 25 mg.of 
vitamin/ 
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vitamin C daily, and it may be that some of them devised 
methods of supplementing their diet. Of these 950, twelve 
developed clinical scurvy, and tests of physical efficiency 
showed that the whole group was in poor condition: e.g. in 
putting a 16 lb. shot, out of 107 men tested not one achieved 
even the comparatively poor throw of thirty feet. Hence it 
appears that an intake of 15 - 25 mg. and a plasma concent- 
-ration of about 0.46 mg /100 cc. are below the level at 
which scurvy is excluded, and are also below the minimum 
compatible with good physical condition. As for the 950 
individuals who received an additional 40 mg. of vitamin C 
each day, although even the very slight amount of absorption 
that took place ( a rise in the average plasma concentration 
from 0.46 to.0.50 mg %) appears to have made a reduction of 
statistical significance in the incidence of scurvy, the 
failure of the plasma levels to rise materially in response 
to prolonged administration of the vitamin makes it manifest 
that most of the additional ration was either not absorbed 
or not utilised. This failure of absorption of utilisation 
explains why the intradermal test revealed no differences 
between the groups; and it makes the comparison of the low 
standards of physical efficiency of Group A with the equally 
low standards of Group E quite pointless. 
In explanation of this failure of absorption or of 
utilisation one can only suggest tentatively that deficiency 
of some other substance may limit the absorption of vitamin 
C. - In respect of this conjecture the work of Kasahara 
and others (92), on the relationship between vitamins B 
and 0, is interesting, although not sufficiently relevant 
for discussion here. 
The findings of Fox and his co- workers have been con- 
sidered in some detail, because their conclusions, if they 
were justified, would contradict the view of practically 
all recent investigators, - that plasma concentrations of 
below 0.5 mg. per 100 cc. are both uncommon and dangerous. 
(H) Standards of Ascorbic Acid. - Some heflections and 
Conclusions. 
It is sometimes insufficiently realised that there is 
a vast difference between the positive condition of health 
and the negative state of absence of disease; between the 
energy and joie de vivre of excellent physical condition, 
with optimum nutrition, exercise, rest, etc., and the state 
of a man who, although suffering from no organic disease, 
carries out his daily work with an effort which leaves him 
listless and apathetic. In the medical profession alone 
there must be many today who, though they regard themselves 
as normal, " healthy " individuals, find that - whether 
sapped by overwork or by rationing or by nervous strain - 
their powers of endurance, their emotional stability, and 
even their ability to concentrate are far less in 1942 than 
i n/ 
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in the days of peace. 
Health, then, is not simply the negation of disease. 
Since anorexia, lowered physical endurance, listless- 
and undue fatigue have for centuries been recognised 
as among the prodromal features of scurvy - " Some show it 
by their lasinesse ", wrote Hawkins in 1569 - it does not 
seem unreasonable to suggest that there may exist a state 
in which the body contains enough ascorbic acid to prevent 
the development of clinical scurvy, but not sufficient to 
prevent the appearance of some of the prodromata: or that, 
in other words, a relative lack of vitamin C ( a defic- 
-iency not great enough to cause obvious disease ) may be 
one of the many factors which can lower human vitality and 
energy. To summarise the steadily accumulating mass of 
evidence that has already converted this hypothesis into 
proved fact does not fall within the scope of this essay: 
but a few examples may be cited : - 
Gander and Niederberger (93), administering additional 
ascorbic acid to elderly persons whose ascorbic acid levels 
had previously been low, recorded increased vitality, 
improved general health, and better sleep among the results. 
Stephenson, Penton and Korenchevsky (94) in 1941 studied 
the effects of administration of vitamins B and C, separ- 
ately and simultaneously, to elderly people, using 40 senile 
patients for their experiment and 18 others as controls: 
their very modest conclusion, that prevention of latent or 
partial vitamin deficiencies would probably result in the 
approach of a less pathological senility, is more than 
confirmed by their results, a few of which can be summarised 
as follows: 
After a course After a course 
of vitamin C. of vitamins B & C. 
Number of cases in which No. of cases in which 
the senile feature was the senile feature was 
Better. Worse. Unchanged. Better. Worse. Unchanged 
Shuffling gait 16 0 9 19 0 5 
Uncertain 
movements 12 1 9 17 0 4 
Impaired 
mentality 13 3 24 25 3 11 
Oedematous 
eye sacs 21 1 10 25 2 5 
Skin rashes 
Insomnia 
6 0 7 10 2 5 
12 2 3 14 1 1 
In 1942 Glazebrook and Thomson (95) found that the 
giving of additional vitamin C to 300 lads of 15 - 20 years 
considerably reduced the duration of tonsillitis, and that 
of these 300 boys not a single one developed rheumatism or 
pneumonia while receiving the supplement, whereas in the 
same/ 
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same number of controls there were half a dozen cases of 
each disease; and, some two years earlier, Hoff and Glaze- 
-brook (96) showed that in British naval trainees the 
incidence of gingivitis in those given supplementary vit- 
amin C was only one quarter of that in trainees receiving 
no such supplement. 
In Germany (97) more than one and a half million 
children of 10 - 14 years were given a daily supplement of 
50 mg. of synthetic ascorbic acid. This was found to 
result in an acceleration of physical development and an 
increased resistance to infection. 
Hirata and Suzuki (98) claimed that administration of 
vitamin C improved patients suffering from progressive 
muscular atrophy; Lyle and LcLean (99) showed that intra- 
-venous injections of ascorbic acid caused a dramatic 
improvement in cases of punctate and phlyctenular keratitis; 
Hunt (100) demonstrated that the healing of a wound is pro- 
- foundly disturbed if the vitamin C content of the body is 
low, a finding that has recently been confirmed, in respect 
of dental extractions, by other workers (101); and Crandon 
and Lund (102) have corroborated that, in volunteers living 
on a scurvy -producing diet, lassitude and fatigue appear 
long before any objective signs of scurvy. 
Despite a few sceptics like Hietschel (103) - who 
anticipated Crandon in voluntarily starving himself of 
vitamin C, and denied the existence of any ill effects at 
the end of a hundred-days of this starvation, although his 
plasma concentration of the vitamin was practically nil - 
there is a great, and steadily growing, mass of published 
work which supports the view that ( in the words of a 
recent leading article in 'The Lancet') " There is a wide 
margin between the amount of vitamin C necessary to 
prevent scurvy .... and the amount necessary for a state 
of well- being. " ( 104) 
We must look, then, for three standards of comparison 
for vitamin C: - the minimal requirement, below which a 
person is in danger of developing scurvy; the optimal 
requirement, or minimum amount compatible with perfect 
health and physical fitness; and, somewhere between these 
two, the "normal" or "average" findings among the popul- 
at large. Is it possible to determine these 
figures, even approximately ? 
The minimal requirement - i.e. the amount necessary 
to obviate the danger of actual scurvy - is fairly easy to 
determine: it has already been shown ( on page 14 ) that a 
daily intake of 25 mg. and a plasma level of 0.46 mg./ 100 
cc. permit the occurrence of an occasional case of scurvy, 
and are therefore just below the minimum. In accepting 
Neuweiler's suggested minimum (105) of 30 - 35 mg. per day 
for an adult, or roughly 0.5 mg. per kilo, we have the 
support/ 
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support of most of the leading authorities on the subject: 
e.g. the League of Nations' Technical Commission on Nutrit- 
ion advocated a minimum intake of 30 mg.(106); Harris has 
found that an intake slightly higher than the League of 
Nations' marginal standard will just reach the minimum 
standard of adequacy as determined by his saturation test 
(57); Scheunert (107) advises 30 - 50 mg. per day; and 
Davidson and Scarborough (86) assert that " The daily min- 
imum requirements of the normal adult male are in the 
neighbourhood of 30 mg." 
The suggested figure of 30 - 35 mg. daily corresponds 
with a blood concentration of 0.5 - 0.6 mg. /100 cc. 
These generally accepted minima - an intake of about 
0.5 mg. per kilo and a blood level of 0.5 - 0.6 mg. /100cc. 
- are the amounts necessary to prevent scurvy, not, as 
some writers (108) have tried to maintain, the ", amount 
necessary for health ". 
It is to be noted, incidentally, that even these 
minimum figures are a little higher than the standard of 
adequacy originally suggested by Harris and others in 1936. 
This is important, because the old Harris standard has 
been employed in some of the work on vitamin C in relation 
to infections. 
"Normal" or "average" figures are bound to vary with 
the country, the season, etc. Perhaps the best estimate 
for Britain is that of Widdowson and Alington (109), who 
investigated the diets of 63 women in time of peace -1935 
- and of 57 women in wartime - 1941 -, and calculated 
that their average intake of vitamin C in 1935 was 57 mg. 
and in 1941 26.9 mg. per day. The last figure is just 
below the "minimum" level, but this can be correlated with 
the fact that cases of scurvy are now less infrequent than 
in pre -war days: e.g. two Edinburgh physicians have seen 
twenty -four cases of fully developed scurvy within two 
years, and Paterson and Daynes have recently commented on 
the increase in scurvy since the outbreak of war. ( 110 & 
111). 
The peacetime average of 57 mg. daily is, however, 
probably a little on the high side: for one thing,most of 
the women investigated were socially of the middle class. 
Perhaps a daily intake of 40 - 50 mg. would be a fairer 
average for normal times. 
In considering the highly controversial question of 
optimum standards, the present writer proposes to start 
with a simple point that appears to have been overlooked 
in the past. - Among the many fluids of which the vitamin 
C concentration has been determined is human milk (112, 
113 & 114). Remembering 
" The marvellous way in which the cells of the 
mammary gland pick out, from the salts of the 
circulating/ 
circulating plasma, exactly these salts which are 
needed for the growing animal, and in the same pro- 
-portions " ( 115), 
and remembering that the mother's diet, age, and condition 
of health are - in the words of Sir Robert Eutchison - 
" almost entirely devoid of any appreciable effect 
on the composition of the milk " (117), 
are we not entitled to conclude that the high level of the 
vitamin in the secreted milk, a level at least twice as 
high as that in the plasma of most mothers, is - to speak 
teleologically - an indication of Nature's decision regard - 
- ing the optimum requirements of the infant ? 
Using the previously mentioned calculations regarding 
the concentration of vitamin C in human milk, and using 
the figures given by Hutchison and Nlottram (118)for an 
infant's requirements of milk, figures which themselves 
tally closely with those quoted by other recognised auth- 
-orities (116), we can draw up a table as follows : - 
Age of child. Lilk required, 
in cc. 
2 weeks 533 cc. 
4 " 633 cc. 
8 " 780 cc. 
12 " 800 cc. 
16 " 866 cc. 
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Lack of definite knowledge as to whether there is any 
diminution in the ascorbic acid concentration of milk in 
the later months makes it unjustifiable to continue the 
table further. It appears, however, that in the early 
months of life nature provides the infant with over 3 mg. 
per kilo of body weight. 
Estimates of the optimum requirements of vitamin C 
vary enormously. Perhaps the lowest is that of Kellie 
and Silva (119), who - in 1939 - contended that a daily 
intake of 15 mg. was sufficient to maintain normal indiv- 
- iduals in good health, - an intake which would give an 
adult less than nature offers to a child of eight weeks, 
and which ( far from being optimum) even falls below the 
minimum figure necessary to prevent scurvy. At the 
opposite end of the scale are the suggestions of Stepp 
and Schroeder (120), who claimed that the optimum intake 
for an adult was 300 mg. daily, and the figures of Everson 
(121), who advocated 7.5 mg. /kilo for children of 3 - 5 
years. 
However, the great bulk of informed opinion appears 
to be converging towards optimum figures of 10 - 20 mg. 
daily for an infant and about five times that for an adult. 
Thus Smith (122) in 1938, after a careful review of the 
literature, suggested that 50 -60 mg. for adults, 40 for 
children, and 20 for infants " may be considered the middle 
or barely adequate consumption level with but little margin 
of/ 
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of safety or allowance for individual variations in 
requirement ". Iatthews and Bacharach (123) claimed, in 
1941, that a young infant required 5 to 10 mg. per day.., 
Holmes and others (124), in 1941, accepted 50 mg, daily 
as the requirement of an average adult. Heinemann (37) 
maintained that an adult needed 60 mg. Sweeney and his 
co- workers (125) in 1941 advocated 50 - 60 mg. daily in 
health and 200 mg. daily in disease. In the same year, 
Davidson and Scarborough (86) in an authoritative review 
of vitamin C declared that the optimum dose for an adult 
was 60 mg. daily, and for an infant at least 15 mg. A 
leading article in the 'British L.edical Journal' (126), 
in 1942, quoting the work of kinot and others in support 
of a satisfactory serum level of 0.7 mg. /100 cc., says,- 
" The most generally accepted estimate of the daily 
requirement of vitamin C by the adult is 50 to 60 
mg. daily, and much more in both chronic and acute 
illnesses." 
The United States National Research Council (127) stated 
in 1941 that the desirable daily intake for an adult was 
75 mg. And, finally, Youmans (128), in his new book on 
"Nutritional Deficiencies: Diagnosis and Treatment ", says, 
"Recently studies based on newer biochemical tests to 
determine amounts needed to maintain a normal body 
store have indicated amounts considerably larger 
than those suggested in the past. On the basis of 
these studies a fair to good but not 'luaus' intake 
for infants would be 20 to 50 mg. daily, for children 
40 to 100 mg., and for adults 50 to 100 mg. " 
Approximate estimates of minimum, optimum and average 
levels may be tabulated thus:- 
Daily intake kg./kilo. Plasma level 
in mg. in mg. /100 cc. 
1. ki nimum to prevent 
danger of scurvy. 
Adult 30 0.43 0.5 - 0.6 
Infant 5 1.5 
2. Optimum. 
Adult 60 0.86 0.8 - 1. 
School child 40 - 60. 1.5 - 2. 1. - 2. 
Pre -sch. " 25 - 40. 2. - 2.5 
Infant 10 - 25. 3. - 3.5 
3. Average (pre -war). 
Adult 40 - 50. 0.6 - 0.7 0.6 - 0.7 
( Wherever there is insufficient evidence regarding plasma 
concentrations, the last column has been left blank.) 
Until the It eiklejohn and Stewart method comes into 
general use exact correlation with excretion is impossible, 
but - on the basis of the dye test - it may be suggested 
that for adults the minimum intake corresponds very roughly 
with a daily excretion of 14 to 20 mg. ( or a concentration 
of .01 to .015 mg. /cc. of urine; the optimum intake implies 
an/ 
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an excretion of round about 30 to 40 mg. per day ( or a 
concentration of about .02 to .03 mg. /cc. of urine); and 
the average adult excretion is probably somewhere in the 
neighbourhood of 20 to 30 rag. ( or a concentration of 
about .015 to .02 mg. /cc. of urine.) 
(2) APPLICATION OF THESE STANDARDS TO INFECTIONS. 
The fops et oripó of much of the work on vitamin C 
in relation to infections is a single case of coryza: in 
1935, while Abbasy and others (20) were investigating the 
excretion of patients on a standard diet, one of their 
subjects developed a mild coryzal fever, and his urinary 
excretion - as estimated by the dichlorophenol - indophenol 
test - fell from a steady level of 19 mg. to 9 mg. and 
remained there for a week. This event led the investig- 
-ators to a study of the effects of pyrexia in general, 
and of various specific illnesses. 
If the early workers on ascorbic acid had cared to 
dip into the records of the past, they would have been 
able to start their researches on the effect of infections 
without waiting for one of their subjects to catch a cold: 
in the days of sailing -ships many a mariner knew that 
scurvy was apt to follow in the wake of a wave of infect- 
ious disease. Numerous instances - too many to be due 
to mere coincidence - are on record of outbreaks of scurvy 
subsequent to epidemics. 
That scurvy is due to deficiency of vitamin C is, 
despite the doubts expressed by hietschel and Lensching 
(103) and Lauber and Bersin (129), too firmly established 
to require further proof. Scurvy as a sequel to acute 
infection implies that the acute infection causes some 
reduction in the bodily reserves of ascorbic acid. This 
reduction might be caused in one of three ways, - by 
excessive excretion, by increased metabolism, or by 
decreased intake or absorption. 
As the amount of published work on vitamin C levels 
in infections is quite considerable, it is cor_vnient to 
start by considering various diseases separately. 
(a) hheumatic Fever. 
In 1936, Abbasy, Hill and Harris (58) tried to inves- 
- tigate the excretion in rheumatic fever and tuberculosis, 
using the dye test and, subsequently, a saturation testa 
their experiment embraced 107 active cases of rheumatic 
fever, 86 convalescent cases of that disease, 88 cases of 
surgical tuberculosis, and 64 healthy children. As all 
the children investigated were in hospitals or other 
institutions, details of diet, etc., were under control. 
It/ 
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It will be remembered ( see page 7 ) that Harris had prev- 
- iously suggested as a standard of adequacy an intake of 
25 mg. for an adult and an excretion of 13 mg. or about 1 
mg. for every 10 lbs. of body weight, - a standard which 
has been shown to be dangerously low. Using this low 
standard, the investigators found that the excretion of 
healthy children and of quiescent cases of surgical tuber- 
-culosis was, without exception, " satisfactory "; that 
active rheumatic cases excreted an average of only 1 mg. 
per stone of body weight ( i.e. only about two thirds of 
the low total then accepted as adequate); and that 83 jo 
of the convalescent rheumatic patients had a " subnormal" 
excretion. Using the more reliable saturation test, they 
found that the rheumatic cases were grossly unsaturated: 
the test doses had to be repeated for 2 to 4 days before 
there was a significant increase in the urinary excretion 
of ascorbic acid; and the response of the controls was 
greater after a single test dose than that of the rheumatic 
cases after their third dose. 
Subsequently (59 & 61), the same workers produced 
further evidence that the excretion of vitamin C was red - 
-uced in rheumatism and tuberculosis, and that the output 
rose during convalescence and healing. 
Lore important, because based on a more reliable means 
of investigation, is the work of Rhinehart and others (83 & 
130) on plasma levels in patients suffering from active 
rheumatic fever. They found that the plasma concentration 
was low, and, since some cases responded slowly to large 
oral dosage, they suggested that absorption was defective. 
They also claimed ( vide infra ) that hypovitaminosis C was 
was of aetiological importance in rheumatic fever. Sendroy 
and Schultz (131), while refuting the claim that lack of 
vitamin C played a part in the causation of the disease, 
found some degree of apparent ascorbic acid deficiency in 
eight of their thirteen cases, even though their standards 
of " normality " were very low. Perry (132), after a study 
of the excretion of eleven rheumatic patients, concluded 
that, while " Vitamin C deficiency is not an important 
factor in the causation of acute rheumatism ", " mild 
degrees of this deficiency are not uncommon in rheumatic 
fever." 
In contradistinction to all these workers, Parsons (41) 
and Keith and Hickmans (133) found an increased excretion of 
vitamin C in acute rheumatism, but their results may well 
have been due to the effect of salicylates. 
The general trend of the evidence relating to ascorbic 
acid in acute rheumatism is to show that the bodily reserves 
are depleted, and that - since the urinary excretion is also 
reduced - this depletion is not the result of an increased 
urinary/ 
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urinary output. The depletion may be due to one or more 
of three factors: there may be defective absorption, as a 
result of digestive disturbance; there may be an increase 
in the metabolism of ascorbic acid; and there may be an 
increased excretion of the vitamin by a route other than 
the urinary one. In connection with the last of these 
possibilities, it is pertinent to recall that Harris (57) 
has recently found that vitamin C is lost in measurable 
amount in the sweat, and that profuse perspiration is one 
of the features of acute rheumatism. 
(b) Tuberculosis. 
In 1936 Hasselbach (134) and Heise and Martin (135) 
independently produced evidence of gross vitamin C 
unsaturation in pulmonary tuberculosis. The last named 
workers subsequently claimed (136) that the urinary 
excretion of the vitamin was inversely proportional to 
the severity of the disease. The published work of 
Heise and Lartin certainly indicates that a considerable 
degree of hypovitaminosis C existed in their tuberculous 
patients: of 106 tuberculous persons tested, the output 
of only 16 reached the very low standard of 14 mg. daily; 
45 excreted between 8 and 14 mg.; and the remaining 45 
excreted less than 8 mg. Despite the various fallacies 
inherent in the dye test, these findings afford definite 
evidence of deficiency. The claim that the excretion of 
the vitamin was inversely proportional to the severity of 
the disease does not, however, appear to be justified by 
the published figures: approximately one third of active 
advanced cases and one third of active moderate cases 
excreted less than 8 mg. per day; and a comparison of 42 
active cases of moderate or advanced tuberculosis with 52 
similar inactive cases shows that the latter 
excreted rather less vitamin C than did the active cases. 
The same workers, this time in collaboration with 
Schwartz (137), brought forward more evidence of the 
extent of hypovitaminosis C in tuberculosis. _Their 
conclusions are reinforced by the results of Hurford (138) 
and by those of Abbasy, Harris and Ellman (61). These 
last investigators found that, although all their cases 
had received a daily supplement of ascorbic acid for four 
weeks prior to the beginning of the experiment, the daily 
excretion of 19 active cases was only 5 to 13 mg., that 
of 6 quiescent cases was 18 to 23 mg., and that of 13 
"moderate" cases was intermediate between the other groups. 
Abbasy and his co- workers also found a correlation between 
the severity of the infection, as shown by the blood 
sedimentation rate, and the excretion of the vitamin, -i.e. 
the more severe the infection the less the excretion. 
Views based solely on urinary excretion might well 
be suspect, but there is ample evidence based on blood 
examinations/ 
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examinations: thus Dagulf (139) in 1939, examining 326 
healthy persons and 255 tuberculous persons, showed that 
- even though the ascorbic acid concentration of his 
supposedly " healthy " group was a little below what is 
usually regarded as normal - the average concentration of 
vitamin C in the blood of the tuberculous patients was 
almost exactly one half of the average for the healthy 
people. Again, the Groth -Petersens (140), using the 
Lund -Lieck methylene blue method, and examining the blood 
of 260 túberculous patients, concluded that such patients 
require a greater amount of ascorbic acid than do healthy 
people, if the serum concentration of ascorbic acid is to 
be maintained at the same level. Sweeney (125), too, in 
1941, found - on the basis of blood and urine examinations 
of a large number of tuberculous patients - that moderate 
tuberculosis was associated with mild hypovitaminosis C, 
and that marked deficiency of the vitamin occurred in 
advanced tuberculosis. 
Lastly it should be mentioned that in 1940 certain 
Liverpool workers (141), estimating the urinary excretion 
of 13 tuberculous patients prior to the therapeutic admin- 
-istration of vitamin C, not only corroborated the usual 
finding of diminished excretion, but also re- affirmed that 
the amount of the ascorbic acid excretion was, roughly, 
inversely proportional to the severity of the infection. 
While this last assertion may or may not be generally 
valid, it does seem that in pulmonary tuberculosis the 
existence of hypovitaminosis C is definitely proved. 
£2ì Pneumonia. 
As early as 1935 Schroeder (142) commented on the 
high degree of vitamin C deficiency commonly encountered 
after pneumonia; and this finding has been confirmed by 
Guldager and Poulsen (143), by Harde and his co- workers 
(144), and by various later investigators. In particular, 
Gander and Niederberger (63) have made hypovitaminosis C 
part of the rationale of their treatment of pneumonia: but 
this will be considered in a later section. 
(d) Pharyngitis. 
In an article with the provocative title, " Ist die 
Pharyna,tis eine C- Hypovitaminose `? ", another Swiss 
workers ías told how, in a patient suffering from severe 
pharyngitis, he found a vitamin C deficiency so gross as 
to suggest that inflammation of the pharynx might be the 
first symptom of scurvy, and of how the pharyngitis 
cleared up without any treatment except oral and parenteral 
administration of vitamin C. This led him to investigate 
thirty -five subsequent cases of pharyngitis, in every one 
of which he found a very marked deficiency of ascorbic acid. 
(e) / 
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je) Other conditions. 
For other infections the great bulk of the published 
work is in accord with the results already cited for acute 
rheumatism, tuberculosis, pneumonia and pharyngitis. Thus 
Woringer and Sala are quoted by Ormerod and Unkauf (146) 
as having observed four cases of scurvy precipitated by 
whooping cough; and Ormerod and Unkauf themselves found 
that the excretion of vitamin C in cases of whooping cough 
dropped almost to zero. Bamberger and Wendt (147) claimed 
that even large doses of ascorbic acid failed to increase 
the urinary output of the vitamin in cases of severe diph- 
- theria. Kundiger and Salus (148) confirmed the existence 
of hypovitaminosis C in diphtheria; and Ghosh (149), Lueg 
and Hamann (150), and others have added their quota to 
the accumulating mass of evidence. kany of these workers 
also tried therapeutic administration of the vitamin, and 
must therefore be considered in a later section. 
That hypovitaminosis C exists in diphtheria and in 
scarlet fever was denied by Godber (18), whose findings 
will be discussed presently. 
As for pyrexia alone, Falke (151) carried out a very 
elaborate experiment just before the outbreak of war: 
measuring the concentration of ascorbic acid in the blood 
of 15 during febrile and afebrile periods, he tried 
to determine the exact amount of the vitamin necessary to 
prevent a fall in the blood level during the febrile periods. 
Falke concluded that approximately a hundred milligrammes 
more of vitamin C were required daily in the presence of 
fever than in its absence. It is to be noted that Falke's 
work does not imply that in pyrexia an additional 100 mg. 
of the vitamin are metabolised daily: not all of the supple - 
-ment is absorbed from the alimentary tract. 
Anomalous Findings. 
In the last few pages twenty -nine separate pieces of 
evidence have been cited in support of what Davidson and 
Scarborough (110) call " The well -recognised finding that 
acute and chronic infections .... are associated with a 
low ascorbic acid content of the blood and urine." Against 
these findings stand the conclusions of Parsons, of Keith 
and Hickmans, and of Godber. 
An overwhelming preponderance of experimental results 
is really enough to decide-a case, but the verdict can be 
given more confidently if the few results not in harmony 
with that verdict can be explained. It seems worth while, 
then, to consider in some detail the evidence that has been 
adduced against the view that infection implies a diminution 
in the ascorbic acid level of blood and urine. 
Parsons/ 
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Parsons (41) studied the excretion of 103 children, 
divided into five groups: (a) 18 children suffering from 
acute rheumatic fever; (b) 12 children with other acute 
infections; (c) 24 surgical cases without any infection; 
(d) 31 children convalescent after rheumatic fever; and 
(e) 18 convalescent after other diseases. He found that 
the majority of the patients in Group (a) excreted more 
ascorbic acid than those of Groups (b) and (c); and that 
the majority of the rheumatic convalescents - Group (d) - 
excreted more than the convalescents of Group (e). He 
used no blood or plasma tests, and the many fallacies of 
the dichlorophenol- indophenol test for urinary vitamin C 
have already been indicated: for example, as his numbers 
were small, the accidental inclusion of an undetected 
cystinuric in either Group (a) or Group (d) might distort 
the average appreciably. Again, working at a time when 
the low standard of adequacy which Harris had originally 
suggested was still in vogue, Parsons might easily have 
included in Groups (c) and (e) a number of children who - 
by modern standards - were suffering from a considerable 
degree of vitamin C deficiency. But the most obvious 
explanation of Parson's findings lies in the fact that 
acute rheumatism is universally treated with salicylates, 
which increase the urinary excretion of ascorbic acid: 
hence the apparent high excretion of Group (a); and the 
output of Group (d) may have been estimated before the 
effect of the salicylates had passed off. 
The same arguments apply 
Hickmans (133), who also dealt 
and who also employed only the 
to the results of Keith and 
exclusively with rheumatism, 
unsatisfactory urine test. 
In his L. D. thesis on " The excretion of Vitamin C 
in certain Infectious Diseases and in Pyrexia ", Godber (18) 
gave a very lucid summary of the relevant literature up to 
1937 ( including brief references to the work of Parsons 
and of Keith and Hickmans, which in both cases was first 
published in January of 1938 ), and then recorded in some 
detail his own findings with regard to the urinary excretion 
of vitamin C - as estimated by the dye test - in 101 
infectious cases immediately after their admission to 
hospital, and in the same patients when convalescent. 
Godber's main results can be rearranged and tabulated 
under two heads, - first, the urinary concentration of the 
vitamin in mg /cc., and second, for patients whose total 
output of urine was measured, the total excretion " on an 
adult basis." - A brief preliminary explanation of this 
second heading is perhaps desirable: direct comparison of 
the total output of children of varying ages is obviously 
useless; therefore, for comparative purposes, the excretion 
of each child has been converted ( by the use of Godber's 
table of standard excretions ) to that of an adult in a 
similar state of vitamin C nutrition: e.g. a child of five 
years / 
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years is shown by the table to excrete 25 ¡o of the vitamin 
C excretion of a similarly nourished adult; hence, if the 
actual output of a boy of five years were 5 mg., he would 
be credited with an adult value of 20 mg. ( N.B. By the 
standards of later workers, Godber's values for the output 
of young children, as compared with adults in a similar 
nutritional state, are unduly low; hence the standardised 
excretions will tend to be too high.) 
Tabulated summaries of Godber's findings are given 
below, the following abbreviations being used to save space: 
S.F. for Scarlet Fever, Dip. for Diphtheria, F.Y. for 
Puerperal Pyrexia, Ton. for Tonsillitis, and O.D. for 
Other Diseases. 
(1) Concentration of vitamin C in mg. /cc. urine. 
Concentration 
in mg. /cc. 
No. 
S.F.Dip.IF.P4TonlO.D.Total 
of acute cases No. 
S.PfDip1.P.P.Ton,O.D,Total. 
of convalescents 
Above .03 5 10 0 2 0 17 0 1 i C 0 0 1 
.021 -.03 9 5 1. 2 3 20 3 0 0 0 0 3 
.015 -.02 8 9 0 1 4 22 3 6' 0 i 
0 10 
.01 -.014 14 7 4 0 0 25 9 10 0 3 2 
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Grand total 48 33 6 8 101 48 33` 6 6 8 
101. 
Ì 
S.F. cases:- Acute stage - Lean concentration, .016mg. 
Convalescents - " " , .009 " 




, .035 " 







No correlation noted between urinary concentration and either severity 
of case or degree of pyrexia. 
(2) Total excretion of vitamin C on an adult basis. 





o. of convalescents. 
O.D ".F.;DipiTon O.D.1Total. 
1 212 0 01 4 
1 111 5 2 1, 19 
0 16 8 1 01_25 
2 57 29 1 3 li 48. 
Excretion of S.F Dip. 
Above 19.5m. 81 9 
13. - 19.5 8 8 
Below 13. 8 3 









Since the diet of convalescents included green vegetables, 
potatoes and fresh fruit daily, tomatoes frecuently, and 
oranges át least every second day, Godber argues that, after 
"at least a.fortnight" of this diet, they can be regarded 
dietetically as normal people; and since the excretion of the 
patients during the acute stage was higher than that of the 
"normal / 
" normal people", he concludes that the urinary of 
vitamin C during the febrile stages of these dfseases fo 
certainly not reduced. 
Godber's assumption that the convalescents can be 
regarded dietetically as normal people reRny begs the 
cuestion: for in conditions where the tissues are heavily 
depleted of vitamin C - as, for example, in Harris's 
experiments mentioned on pie 6 - it takes considerably 
more than e fortnight of adequate diet to restore the lost 
reserves. 
koreover, in the lit of the knowledge of vitamin 
C recuirements and standards that has accumulated in the 
four years subsequent to Godber's experiments, the first 
point that strikes one is that, for " normal people" 
receiving a diet fairly generous in vitamin C, practically 
every convalescent had a remarkably low output of the 
vitamin. 
At the ti e when these experiments were carried :_7 
Harris's original standard of adequacy - a concentrat:= 
above .01 to .02 mg./cc. of urine, or a total adult out:P.t 
of above 13 to 27 mg. - was still accepted. Godber realised 
that this standard, being founded on a " reputed mini al 
optimal dose" which itself was based on the cuite valueless 
cuff test, had no valid basis, but, unfortunately, he 
thought it was too high, and therefore disregarded the fact 
that half of his convalescents were below even Har_fsts 
minimum figure. As has been shown, Harris's ::'::al 
standard was, in point of fact, di,ni;erously low: a lo-rel 
of .01 mg. of vitamin C per cc. of urine ; :: a total output 
of 13 mg.) is not even incompatible rith the develc::_ent of 
scurvy. Yet, out of 73 convalescents examined, 35 has a 
concentration lower than .01 mg./cc.; and,of 46 convalescents 
whose total excretion was measured, that of 25 fell below 
the 13 mg. line. 
If we accept a concentration J,f = fL.)ce. or an 
adult excretion of 19.5 mg. as the 2o7et standard 
of normality ( see page 20 ), - a standard fa:- below what 
re would expect in normal people who were fed according t: 
the generous diet of an L. C. C. hospital -, t. en, ct of 
73 convalescents, only 14 reached a normal concentration 
( and of these only 4 were above normal). Concentration. 
however, is an uncertain guide, since it may vary accordi::,: 
to the amount of urine passed. On the safer ground of 
total excretion, out of 48 convalescents Those output was 
calculated, only 4 reached a standard of n=ality. ( These 
4, incidentally, consisted of to mild cases cf diphtheria 
and 2 of scarlet fever.) 
When we find that, after at least a fortnight's 
convalescence during which they received a diet rich in 
vitamin/ 
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vitamin C, only 4 mild cases attained anything like a normal 
excretion, as compared with 44 whose output was grossly 
subnormal, we can only conclude that the depletion of the 
ascorbic acid reserves during the acute stage must have 
been very considerable. 
No useful purpose can be served by comparing the 
excretion during the acute stage with the markedly sub- 
-normal excretion of convalescence. 
Taken by themselves, the concentrations during the 
acute stage do not seem to be much diminished, except in 
Scarlet Fever ( where half of the patients had a concent- 
-ration below the lower limit of normality ), and in the 
Puerperal group ( where only one patient attained a normal 
level); but the possibility of febrile oliguria makes the 
concentration - at no time a really reliable guide - a 
wholly unreliable index. Adopting the safer criterion of 
standardised excretion, we find that the excretion was sub- 
-normal in 66.7 of the acute cases of scarlatina, 55 ¡o of 
the acute cases of diphtheria, 100 ¡o of the puerperal 
cases, and 60 ; of tonsillitis cases. These figures, 
however, mean little, as we do not know the previous nutrit- 
-ional state of the patients. 
In support of his contention that infection does not 
lower the excretion of vitamin C, Godber points out that 
there is no correlation between the excretion and either 
the severity of the case or the degree of pyrexia; but, in 
respect of the excretion at the start of the illness, the 
possibility of any such correlation is ruled out by the 
presence of another variable, namely, the previous levels 
of ascorbic acid in the tissues of the patients. It is 
only in patients who had received similar diets prior to 
the onset of the infection that we could expect any such 
correlation. As for the excretion in convalescence, in 
view of the many possible fallacies of the dye test, the 
numbers are too small for us to expect to find a high 
degree of correlation; yet it is interesting that, out of 
10 scarlet fever patients with an initial temperature of 
100° or more, 7 had a convalescent concentration below 
the average for the convalescent scarlet group; and that, 
out of 8 cases of severe diphtheria, 5 had a convalescent 
concentration below the average for that disease. Even 
more interesting is an analysis of the 15 diphtheria 
cases of which the total excretion was ascertained -during 
convalescence: 
No. of cases with total excretion 
Under 13 mg. 13 - 19.5mg. Over 19.5mg. 
8 severe or moderate 
cases 5 3 0 
7 mild cases 3 2 2 
Incidentally/ 
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Incidentally, Godber's cases of puerperal pyrexia 
suggest a relationship between the duration of the pyrexia 





Vitamin C output 
two days later. 
88 days 10.2 mg. 
48 " 11.1 mg. 
19 " 13.6 mg. 11.7 mg. 
16 " 12.4 mg. 13.0 mg. 
8 " --- - -- 
3 " 16.9 mg. 13.5 mg. 
Godber's error in assuming that his convalescents, 
after "at least a fortnight" of full hospital diet, could 
be regarded, in respect of ascorbic acid nutrition, as 
normal people - a mistake easy enough to make in 1938 when 
knowledge of the normal standards for vitamin C was most 
incomplete - invalidates his conclusions but does not 
detract from the sterling value of his work: although he 
employed only a single test of 'very limited accuracy, his 
careful study of the excretion of ascorbic acid in infect- 
ious diseases is recorded with such precision and detail 
as to make it possible for subsequent workers, utilising 
information unknown in 1938, to draw valid conclusions 
from his experiments. - In particular, the fact that, 
after a full fortnight on a generous diet, 91.7 % of his 
convalescents had a grossly subnormal excretion of the 
vitamin affords additional evidence of the extent to which 
the bodily reserves become depleted in infectious diseases. 
(g) Conclusions regarding application to infections of 
standards for vitamin C. 
All the evidence indicates that infectious disease 
lowers the ascorbic acid content of the tissues. While 
this at once suggests that, in order to restore the tissue 
concentrations to normal, the diet of convalescents should 
be rich in vitamin C, we have still to consider whether 
the depletion is so drastic as to warrant administration 
of the vitamin during the acute stage. 
Yavorsky and others (152), Ingalls (153), karinesco 
et alii (154), Sweeney and his co- workers (125), and 
others have investigated the amount of ^scorbic acid in 
various organs and fluids. On the basis of such work 
the vitamin C content of the adult body may be assessed 
at about 1,000 mg. in an average person and about 3,000 
mg. in a saturated person. Of the normal 1,000 mg. of 
vitamin C, some 200 - 250 mg. are stored in the liver, 
about 20 - 30 mg. are in the blood, and considerable 
amounts are present in the adrenals, brain, kidney, 
pancreas, spleen, heart and lung. 
Now/ 
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Now Falke, as already mentioned on page 24, found 
that, to maintain the blood ascorbic acid at a constant 
level during a febrile illness, an extra 100 mg. were 
required daily. If his figures are accepted as accurate, 
it follows that, where pyrexia lasts for not more than 
three days, failure to supply extra vitamin C will result 
in the tissues becoming depleted only to the extent of 
less than one third of their normal total content. 
The provision of additional ascorbic acid during 
prolonged febrile illnesses is an obvious necessity: as a 
recent leading article in the 'British Medical Journal' 
(126) put it, speaking of pulmonary tuberculosis, - 
" Without supplementary administration of vitamin 
C, the store ( of the vitamin ) is dissipated in 
advanced tuberculosis before death, sometimes to 
a negligible quantity." 
For fevers of short duration, however, such as varicella 
and the mild scarlatina of recent years, the suggestion 
thát " the generally accepted amount of 50 to 60 mg. daily" 
should be increased to about 200 mg. (126) seems to lose 
force. Unless it can be shown that administration of 
vitamin C during the febrile period ( when the amount of 
waste through non -absorption is likely to be considerable) 
favourably influences the course of the disease, it may 
well be maintained that, for fevers of short duration, no 
harm will be done by allowing the body to become tempor- 
-arily depleted of one third of its vitamin C, so long as 
the diet in convalescence ( when absorption is easier ) 
contains not merely sufficient ascorbic acid for normal 
maintenance but a surplus to enable the bodily stores to 
be built up again. For transient pyrexias, then,.a 
convalescent diet containing ample fresh fruit and green 
vegetables may well suffice: administration of synthetic 
vitamin C during the acute stage cannot be regarded as 
necessary unless it can be shown that such administration 
has a beneficial effect during the actual period of illness. 
(3) r,F.'ECTS OF VITAMIN C " IN VITRO ", AND 
EXPERIMENTS ON LABORATORY ANIMALS. 
Although logically this section should be divided 
into two sub -sections, dealing with " test -tubes " and 
" guinea -pigs " respectively, it is felt that a clearer 
picture will be obtained by taking various organisms 
separately. 
H. Pertussis. 
Otani ( 155 & 156 ) claimed that, when cultures.of 
H. Pertussis were grown on solid media, an addition of 2.5 
mg. / 
mg. of vitamin C to every cc. of medium had a definite 
retarding effect on the growth of the organisms; and when 
the amount of ascorbic acid was increased, the inhibitory 
effect became more marked, until finally death of the 
organisms occurred. Similar results were reported almost° 
simultaneously by Grootton and Bersonoff (157). It is 
to be noted, however, that the concentration required to 
produce this retarding effect is tremendously high, about 
a hundred times as high as we could hope to achieve in the 
circulating human blood, and that the inhibitory action 
might conceivably be due merely to alteration in the pH of 
the medium. 
Otani also found that, when the quantity of vitamin 
C added was 1.2 - 1.8 mg./ cc. of medium, normal growth 
occurred, but the organisms were of diminished virulence: 
when injected into rabbits they caused only a leucocytosis, 
instead of the expected leucocytosis with relative lymph- 
-ocytosis. He showed, too, that, if ascorbic acid were 
added to the toxin of H. Pertussis, the effect of the 
latter when injected intradermally into rabbits or guinea - 
-pigs was markedly reduced; and that, if the untreated 
toxin were injected into animals which had previously been 
dosed with ascorbic acid, the effect was again diminished. 
1). C. Diphtheriae. 
As early as 1935, Jungeblutt and Zwemer (158) claimed 
that vitamin C hadsome power of inactivating diphtheria 
toxin, and that animals treated with the vitamin reacted 
less severely to subsequent intradermal injections of the 
toxin. Following up this line of investigation, Kligher 
and his co- workers (159) found that the addition of vitamin 
C to cultures of C. Diphtheriae reduced their toxigenicity, 
as estimated by intradermal tests in the same animals. They 
also contended that preformed diphtheria toxin was, in 
vitro, partially inactivated by the addition of ascorbic 
acid. Attempting to refute this last claim, Torrance 
(160) suggested that the rapid disappearance of the vitamin 
in incubated toxic filtrates is due to the toxin rapidly 
inactivating ascorbic acid by a reversible oxidation. 
Investigating the effects of a lethal dose of toxin, 
Harde and Benjamin (161) ascertained that, in guinea -pigs 
dying from the effects of an injection of diphtheria toxin, 
the ascorbic acid content of the suprarenals and liver was 
markedly subnormal; and these organs ( together with the 
brain and kidneys ) are the very ones in which the ascorbic 
acid content falls sharply when guineapigs are fed on a 
hypovitaminous diet, - as has been shown by Yavorsky and 
others (152), Lalmberg and Euler (162), and Wortis, Wortis, 
and IJar sh (163). 




the suprarenals and liver after a fatal dose of diphtheria 
toxin was confirmed by Kligher et alii (159), by Careddu 
and Wilzer (164), and by Harris, Passmore and Pagel (165). 
The last named workers found that, although the fall was 
more striking after diphtheria toxin, a similar fall could 
be produced by injecting the toxins of certain members of 
the Salmonella and Pasteurella groups or by the injection 
of E. Tuberculosis; and Harde and Benjamin - following up 
their original experiment - discovered that the liver and 
suprarenals were largely depleted of vitamin C after the 
injection of the toxin of diphtheria, tetanus, dysentery, 
or mouse typhoid. 
Torrance (166) corroborated that a lethal dose of 
diphtheria toxin reduced the ascorbic acid content of the 
suprarenals almost to nil. He also found that, curiously 
enough, the injection of half of a minimum lethal dose 
caused a rise in the suprarenal content within forty -eight 
hours, while one third of a minimum lethal dose caused a 
rise within twenty -four hours. 
Flori (167) reported that administration of vitamin 
C benefited guinea -pigs suffering from diphtheria, and he 
suggested that the vitamin enhanced the action of diphtheria 
antitoxin. Lore recently, Luck and Hall (168) have 
confirmed Jungeblutt's original suggestion that guinea -pigs 
treated with vitamin C withstand diphtheria toxin far more 
satisfactorily than untreated controls. 
Other workers (169 & 170) have used ascorbic acid 
along with adrenal cortex hormone, and have claimed that 
diphtheritic toxaemia is less severe in rabbits so treated 
than in control animals. 
Finally, Szent -Gyorgyi's experiments on guinea -pigs 
" Show that whereas 1 mg. daily prevents the onset of 
obvious signs of scurvy, about 2 mg. is needed for normal 
tooth development, and 3 or more to protect the animal 
from injury by injection of diphtheria toxin." (171). 
ICI M. Tuberculosis. 
LcConkey and Smith (172) kept 37 guinea -pigs on a 
diet containing no vitamin C and 25 guinea -pigs on a diet 
rich in the vitamin. All the animals were then fed with 
tuberculous sputum. Only two of the 25 guinea -pigs which 
had received.ample ascorbic acid developed tuberculous 
enteritis, as compared with twenty -six cases in the 37 
hypovitaminous animals, - a difference which is, of course, 
statistically significant. 
That vitamin C afforded some protection against 
tuberculosis was denied by Heise and Lartin (173): they 
induced / 
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induced a hypervitaminosis C in 10 out of 15 guinea -pigs, 
and subsequently infected all the animals with tuberculosis. 
However, even if the inadequacy of the numbers tested be 
disregarded, this experiment proves little: a dose of Ìi. 
Tuberculosis sufficiently potent to infect every single 
guinea -pig is obviously no criterion by which to decide 
whether the state of vitamin C nutrition' has any bearing 
on the animals' powers of resistance to infection. 
Similarly, the finding that prolonged medication with 
vitamin C does not protect guinea -pigs against a lethal 
injection of tuberculin (174) is not evidence for or 
against the claim that animals treated with the vitamin 
have a greater power of resistance than untreated controls. 
Indeed, the very workers who first showed that ascorbic 
acid does not confer immunity against a lethal dose of 
tuberculin have recently produced evidence (175) to prove 
that daily injections of vitamin C benefit tuberculous 
guinea -pigs. 
Birkhaug's conclusions are in substantial agreement 
both with these claims regarding the therapeutic effect of 
ascorbic acid and with L.cConkey's findings regarding its 
prophylactic effect. Birkhaug (176) reported that 
hyper- vitaminosis C caused a significant increase in the 
body weight of guinea -pigs and a reduction in the frequency 
of tuberculous lesions; and that daily oral administration 
of the vitamin significantly inhibited the tuberculin 
reaction in tuberculous guinea -pigs, while the degree of 
inhibition was correlated with the level of urinary 
excretion and with the suprarenal content of vitamin C. 
These reports are reinforced by the observations of 
Osborn and Gear (177), who have pointed out that those 
mammalian species which can synthesize vitamin C are the 
ones most resistant to tuberculosis. 
(B), Coccaceae. 
Layer (178) showed that vitamin C inhibits the growth 
of pneumococci and streptococci. Earlier workers (179 & 
180) had commented on the fact that, when an animal is 
deprived of ascorbic acid for a long time, instead of 
developing scurvy, it usually develops pneumonia. 
Rhinehart (181) asserted that, if guinea -pigs were 
deprived of vitamin C and then infected with haemolytic 
streptococci, the resultant lesions closely resembled 
those found in rheumatic fever in man; but subsequent 
workers have pointed out that Rhinehart's lesions were 
simply those found in guinea -pigs deprived of vitamin C: 
they were not lesions due to streptococcal infection. 
Busing (182) found that daily intramuscular or 
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intravenous injections of ascorbic acid into rabbits or 
rats infected with pheumococci increased their survival 
time, as compared with that of controls which received no 
extra ascorbic acid; and Locke and his co- workers (183) 
claimed that the administration of vitamin C improved the 
resistance of rabbits to Type I Pneumococcus, and also 
enhanced the action of sulphanilamide treatment. 
For pneuraococcal lesions in experimental animals, 
as for tuberculous and diphtheritic conditions, there is, 
therefore, a fair amount of evidence in support of the 
view that ascorbic acid is beneficial. 
j ) Other Organisms. 
Patocka and Ilaysky (184) have shown that, in vitro, 
ascorbic acid promotes the growth of strict anaerobes, a 
result, presumably, of its reducing property; but, since 
this enquiry is not concerned either with the genus 
Clostridium or with the common cold - the virus of which 
is said (185) to be a strict anaerobe - the effect of 
the vitamin on anaerobes is hardly relevant. 
Jungeblutt (186) has claimed that, within certain 
narrow limits of concentration, ascorbic acid inactivates 
the virus of poliomyelitis. He has also reported (187 
188) that treatment with the vitamin confers some measure 
of protection on monkeys incubating poliomyelitis after 
experimental infection. However, Sabin (189) has been 
unable to find any evidence of even partial protection in 
similar circumstances. 
(F). Anaphylactic Shock. 
In 1939 Diehl_ (190) investigated the effects of 
different states of vitamin C nutrition on anaphylaxis. 
He found that, in guinea -pigs suffering from a mild hypo - 
-vita inosis C, anaphylactic shock was more severe than 
in normal animals, and more frequently ended fatally; on 
the other hand, in guinea -pigs suffering from a severe 
degree of hypovitaminosis ( or from avitaminosis ), an 
anaphylactic reaction was hard to produce, and, when 
produced, was relatively mild. Diehl tried to explain 
his findings by postulating that in mild hypovitaminosis 
the reticulo- endothelial system produces a small amount 
of antibodies, whereas in avitaminosis it produces 
practically none. 
Subsequently, a Japanese worker (191) discovered 
that, in guinea -pigs sensitised to horse serum, he could 
prevent or minimise anaphylaxis by giving an injection of 
ascorbic acid immediately before the _second dose of horse 
serum. 
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(4) THERAPEUTIC ADMINISTRATION OF VITAMIN C IN INFECTIONS. 
jAj Tuberculosis. 
The evidence in regard_to tuberculosis is abundant 
but conflicting, although the great majority of published 
reports indicate that the therapeutic administration-of 
ascorbic acid is not devoid of beneficial results. 
In America, Radford and his co- workers (192) divided 
111 cases of advanced pulmonary tuberculosis into three 
groups; patients in Group C received 250 mg. of vitamin C 
daily, members of Group 0 were given 500 cc. of orange 
juice, and Group Co was a control group receiving no 
dietetic supplement. At the end of a three months 
course of treatment, Group C showed an improvement over 
the control group in respect of haemoglobin, erythrocyte 
count, monocyte /lymphocyte ratio, and neutrophil /lymphocyte 
ratio, while Group 0 was intermediate between the other 
groups; but repetition of these tests some three months 
later showed that the differences had been transient, and 
clinical examination failed to reveal any significant 
difference between the three groups. In Austria, Weber 
(193) claimed that administration of ascorbic acid caused 
a definite regression of infiltration. In Germany, Pilz 
(194) and Hasselbach (195 & 196) noted that treatment of 
active pulmonary tuberculosis with vitamin C was followed 
by definite clinical improvement, with better appetite, 
increase in weight, and reduction of night sweats. In 
Italy, Capelli (197) found that daily intravenous injection 
of vitamin C for ten doses was useful for certain cases of 
haemoptysis due to pulmonary tuberculosis. Writing in 
the "British journal of Tuberculosis ", Heise and others 
(198) maintained that five daily intravenous injections 
of the vitamin produced a fall in the blood sedimentation 
rate. Improvement in the blood sedimentation rate and 
increase in the body weight were recorded by Albrecht (199) 
as beneficial results of the administration of ascorbic 
acid. Similar claims for slight degrees of improvement 
have been made by Fetter (200), Hurford (138), Bakhsh and 
habbani (201), etc. 
Incidentally, it should be noted that, if - as Schneider 
and Widman (202) have reported - high dosage with vitamin C 
lowers the blood sedimentation rate of normal individuals, 
the fact that administration of the vitamin reduces the high 
blood sedimentation rate of pulmonary tuberculosis does not, 
er se, necessarily indicate any beneficial action as regards 
the actual disease. 
Again, Sweany (125) found that ascorbic acid was very 
useful in advanced tuberculosis, decreasing sputum, improving 
general / 
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general condition, and prolonging life; and Cruickshank 
and .heaver (203) postulated the presence of a " Vitamin C 
hunger " in active tuberculosis. 
On the other hand, Dagulf (204), after a careful and 
comprehensive study of past work and of his own experiments, 
concluded that - although the vitamin C content of blood 
and urine is definitely reduced in tuberculosis - there is 
no proof that ascorbic acid therapy is beneficial. This 
conclusion is supported.by the work of Erwin, Wright and 
Doherty (141), who endeavoured to treat seven acute cases 
with marked pyrexia and seventeen " bad chronics " with 
100 - 200 mg. of vitamin C daily for six months; of the 
twenty -four cases so treated, eleven died during the 
investigation, and of the remaining thirteen - all of whom 
remained sputum positive - the results might be summarised 
as follows:- 
Improved. Unchanged. Worse. 
X -ray appearance 1 0, 12 
Pyrexia 2 7 4 
Pulse 2 7 4 
Amount of sputum 0 5 8 
Weight 3 1 9. 
As for complications,- 
" Several of the patients were suffering.from 
laryngitis or enteritis, but in none of the 
survivors was any improvement in these 
complications noted "; 
two patients developed haemoptysis while under treatment, 
and one developed meningitis. Admittedly the study of 
Erwin and his co- workers suffers from certain defects: 
the number of cases investigated is small, all the cases 
were very advanced, and the absence of controls is most 
unfortunate. Yet these defects hardly seem sufficient 
to warrant the complete rejection of'the testimony of the 
three Liverpool workers. 
The investigators who maintain that ascorbic acid 
is not beneficial - Erwin and his colleagues, Dagulf, and 
one or two writers quoted by Dagulf - may form only a 
minority, but they are a minority too strong to be ignored. 
While it is indisputable that in tuberculosis the body 
becomes depleted of its store of vitamin C, and while 
measures to remedy that depletion seem entirely reasonable, 
the question of whether the administration of ascorbic 
acid does anything to reduce the severity of the disease 
must be regarded as still open. 
jB Rheumatic Fever. 
In view of the low level of vitamin C in urine and 
in plasma in cases of rheumatic fever, a number of workers 
have endeavoured to ascertain whether administration of 
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the vitamin would have any effect on the course of the 
disease. Schultz (6) divided 56 advanced rheumatic cases 
into two equal groups: members of Group A received 100 mg. 
of vitamin C daily, while the patients in Group B were 
given 100 mg. of lactose; and there were more relapses in 
Group A than in Group B. He then tested the effect of 
intravenous and oral ascorbic acid on 44 cases of acute 
rheumatic fever, and found no clinical improvement in 
patients so treated. 
With these conclusions Faulkner (205), Sendroy and 
Schultz (131), and others have agreed: the clinical 
manifestations of acute rheumatic fever are not demonstrably 
affected by oral or intravenous administration of vitamin 
C over periods of several months, or by large doses of 
orange juice. 
(C) Whooping Cough. 
As contrasted with the doubtful results obtained in 
pulmonary tuberculosis and the negative results in acute 
rheumatism, the findings in whooping cough are positive: 
administration of vitamin C to patients suffering from 
whooping cough has been uniformly recognised as beneficial 
by the few workers who have published reports of their 
investigations of this line of treatment. 
Otani (155) employed parenteral vitamin C as the 
only treatment in 81 cases of whooping cough, including 
some with associated bronchitis or pneumonia. For mild 
cases he gave intravenous or intramuscular injections of 
50 - 100 mg. daily for 5 - 12 days, and for severe cases 
rather larger injections for a similar period. In 66 
cases ( or 81.5 %) the results were good, the spasmodic 
cough improved greatly after one to two weeks, and the 
blood picture approximated to normal within ten days. 
While it was with uncomplicated cases that ascorbic acid 
treatment was most successful, three severe cases " in 
which a fatal issue was threatened " recovered under this 
treatment. In the 15 cases ( or 18.5 %) in which the 
ascorbic acid therapy was unsuccessful there were usually 
complications, such as asthma, tuberculosis, or simult- 
- aneous measles. On the basis of these results Otani 
concluded that, 
" Treatment with vitamin C may therefore be 
regarded as a specific procedure. In contrast 
with other methods of therapy, this treatment 
shows no side effects, even when unnecessarily 
large doses of vitamin C are given. It posEesses 
the advantage, when used for pertussis in infants, 
of giving good results at an age when, by reason 
of the inadequate production of antibodies, 
success 
with specific vaccines is difficult to obtain." 
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Ormerod, UnKauf, and White (146) treated 17 cases 
of Dertussis with oral vitamin C, the dosage given being 
- irrespective of age - 350 mg. on the first day, 250 mg. 
on the second and third days, 200 mg. on the fourth and 
fifth days, 150 mg. on the sixth and seventh days, 125 mg. 
on the eighth and ninth days, and then 100 mg. daily till 
all symptoms vanished. They found that treatment with 
vitamin C caused changes in the following order: 
" (1) Larked reduction or complete arrest of vomiting; 
(2) Reduction or disappearance of night cough; 
(3) Reduction in number or intensity of whoops; 
(4) Reduction in number or intensity of day coughs." 
They concluded that ascorbic acid therapy reduced the 
duration of the disease from a matter of weeks to a matter 
of days. 
These experiments were perhaps open to criticism on 
the ground of absence of controls. This criticism is 
not, however, valid in respect of Gairdner's investigation 
(206). Gairdner studied,41 cases which fulfilled one 
or more of the following conditions: (a) H. Pertussis 
recovered from cough plate; (b) Typical paroxysmal cough 
ritnessed; and (c) Suggestive history accompanied by either 
sublingual ulcer or marked lymphocytosis. Of these cases, 
21 received vitamin C, the dosage employed being 200 mg. 
daily for the first week, 150 mg. daily for the second 
week, and 100 mg. for the third week. The other 20 cases 
received cod liver oil, bromide and belladonna. Although 
the vitamin C was not always administered at the start of 
the disease, Gairdner found that there was a significant 
decrease in the total duration of illness in the group 
treated with ascorbic acid: the average duration in the 
treated group was 35 days, as compared with 41 days in the 
control group. 
Li Pneumonia. 
As an introduction to the report of their experiments 
Gander and Niederberger (63) gave an interesting summary 
of the evidence that led them to enquire whether ascorbic 
acid therapy might be beneficial in pneumonia. Their 
main points are: 
1. The time -honoured administration of fruit and 
fruit juices in febrile conditions, including 
pneumonia; 
2. The surprisingly high degree of vitamin C 
deficiency commonly found after pneumonia; 
3. The frequent occurrence of pneumonia in animals 
fed on scurvy -producing diets; 
4. The high correlation between the seasonal 
mortality from pneumonia and the seasonal 
frequency of vitamin C deficiency; 
and 5. The increased mortality from pneumonia in the 
:elderly, in whom vitamin C deficiency is generally 
most marked. 
They / 
They treated 15 cases of pneumonia with vitamin C orally 
or intramuscularly. Usually the administration of 
ascorbic acid was additional to the ordinary pneumonia 
therapy, but in one case oral treatment with vitamin C 
was successfully applied without any other medicaments. 
The findings in these 15 cases suggest that ascorbic acid, 
particularly if given early, favourably influences the 
course of the disease: pain subsides, thus permitting of 
a reduction in the exhibition of narcotics, and 
" The general condition of the patient is always 
benefited in a striking manner, and convalescence 
runs a better and more rapid course than in 
pneumonias which are not treated with vitamin C. 
An impaired percussion note, bronchial breathing 
and adventitious sounds certainly persist for a 
while, since the healing process cannot immediately 
follow on the resolution of the diseased tissues. 
No cases of failure have yet been recorded, although 
the condition of some of the patients treated was 
very serious." 
Gander and Niederberger varied their dosage according 
to the amount of vitamin C deficiency as estimated by urine 
tests. On an average, however, their recommended dosage 
is in the neighbourhood of 2,000 mg. in one - for 
cases with gastro- intestinal disturbances about four 
injections of 500 mg., and for cases without alimentary 
upset, one intramuscular injection of 500 mg. followed by 
1,200 mg. orally during the next few hours. 
They concluded that, 
" Correction of the state of vitamin C deficiency 
on the first day of the attack of pneumonia brings 
about such strikingly favourable results as to 
warrant the inference that vitamin C represents a 
valuable addition to the therapy of pneumonia. " 
As a corrective to these enthusiastic claims it must 
be pointed out that Gander and Niederberger have recorded 
details of only four of their fifteen cases, and that, 
even for these four, the information provided is inadequate. 
Hochwald (207) treated 13 cases of croupous pneumonia 
solely with intravenous injections of ascorbic acid. He 
found that 
" The improvement in general condition ( prostration, 
dyspnoea ) is particularly striking; it becomes 
apparent after the very first injections, and is 
quite marked even while the pyrexia persists. The 
more rapid return of temperature .to normal is 
another feature; it is accompanied, or often 
preceded, by a sudden decrease in the leucocyte 
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" count, and morphological improvement of the blood 
picture. The clinically, or more often radiolog- 
-ically, demonstrable infiltration of the lung 
parenchyma, which usually persists for several weeks 
after the temperature has returned to normal, 
retrogressed very early in our cases. " 
Hochwald's dosage was 500 mg. every two hours until the 
temperature fell. 
Vogl (208) treated lobar pneumonia and broncho- 
pneumonia with ascorbic acid, giving 200 - 500 mg. twice 
daily for several days. In lobar pneumonia he found . that 
remarkable changes were observed in the temperature chart: 
within 24 hours the morning temperature was normal; and 
during each day the temperature rose to a lower maximum 
than on the previous day, until on the fourth or fifth day 
it remained normal. Also, cyanosis, dyspnoea, and 
restlessness were less marked than in other cases. The 
physical signs, however, did not disappear any more quickly 
than in untreated cases. 
In broncho -pneumonia, too, the symptoms were less 
troublesome, and the temperature behaved as in lobar 
pneumonia, except that it took longer to reach normal. 
In all, Vogl had two deaths in his 37 cases of 
pneumonia treated with vitamin C. 
Vogl also claimed that vitamin C was a useful 
prophylactic against the development of post - operative 
pneumonia, a claim that has recently been refuted by Lund 
and Crandon (102). 
(E) Diphtheria. 
The evidence relating to diphtheria is confused and 
contradictory, and no worker has yet produced a series of 
treated cases and controls of sufficient magnitude to 
decide the case one way or the other. 
As early as 1935, Bamberger and Wendt (147) attempted 
to treat malignant diphtheria with vitamin C. In view 
of the well known post -mortem finding of pathological 
changes in the suprarenals in fatal cases of diphtheria, 
and in view of the equally well known fact that neither 
large doses of antitoxin nor circulatory stimulants will 
prevent circulatory failure, these workers had previously 
tried to treat circulatory failure with extract-of suprarenal 
cortex, but without success. They now continued to 
administer suprarenal extract, but - because the normal 
suprarenal is especially rich in vitamin C - they also gave 
ascorbic acid, in doses of about 500 mg. per day for two 
days, usually orally. 
Applying / 
Applying this treatment - suprarenal extract and 
vitamin C to eight clinically hopeless cases, they were 
able to record five recoveries, while in the three failures 
" death was postponed four to five days." 
Following up this line of treatment, Bamberger and 
Zell (209) reported that, out of 41 cases of very toxic 
diphtheria treated with suprarenal extract and ascorbic 
acid, 22 had survived, - a result which Bamberger and Zell 
regarded as satisfactory, but which seems meaningless in 
the absence of any statement of the mortality rate for 
equally toxic cases when given no suprarenal extract or 
ascorbic acid. 
Iautner (169) and Dieckhoff (170) concluded separately 
that, although vitamin C and suprarenal extract definitely 
benefited experimental animals, clinical trials on human 
beings were not very encouraging. Even more disappointing 
were the results of Engelhard (210) who used the alternate 
case method: of 28 patients treated with vitamin C and 
cortical extract, seven died; in 27 controls there were 
eight fatalities. 
On the other hand, Otto (211) revived the claim that 
both ascorbic acid and suprarenal extract appeared to 
exercise a favourable influence on the course of malignant 
diphtheria. 
(2) Other infections. 
Heaslip (212) found that a low state of vitamin C 
nutrition predisposed to infection by the virus of 
poliomyelitis and also increased the severity of attack. 
Korbsch (213) claimed that ascorbic acid in large doses 
gave excellent results in the treatment of head colds and 
acute rhinitis. Dainow (214) treated a few cases of 
herpes zoster by daily injections of 100 mg. of vitamin 
C, and found that, under this treatment, the lesions 
rapidly disappeared and the pain subsided. 
In an investigation involving 300 cases Glazebrook 
and Thomson (95) showed that ascorbic acid reduced the 
duration of tonsillitis. Baer (145) successfully 
treated 36 cases of pharyngitis with the vitamin. Kellett 
(216) advised the use of vitamin C - in addition to 
neoarsphenamine - in Vincent's angina. Villela (216) 
found that in skin leprosy vitamin C had little real value, 
apart from possibly increasing slightly the tolerance to 
chaulmoogra preparations. Gerdjikoff (217) studied twelve 
cases of malaria treated with ascorbic acid in addition to 
ordinary antimalarial drugs: he concluded that ascorbic 
acid, given in addition to specific therapy, was very 
beneficial in malaria. 
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Najib -Farah (218) treated enteric fever with intra- 
-venous injections of vitamin C and extract of suprarenal 
cortex, and reported that this treatment gave immediate 
beneficial results. And Cammarella (219) found that in 
dysentery administration of ascorbic acid was valueless. 
With the exception of the work of Glazebrook and 
Thomson, the experiments mentioned in the previous three 
paragraphs were all conducted on a limited scale, and the 
various results are suggestive, rather than conclusive. 
(G) Experimentally induced fever. 
Haas (220) analysed the effect of ascorbic acid on 
experimentally produced pyrexias, and showed that, while 
the vitamin prevents a rise of temperature in those cases 
where the pyrexia is due to drugs which affect the 
peripheral temperature regulation (e.g. dinitrophenol and 
thyroxin ), it does not prevent the rise of temperature 
in cases where the pyrexia is caused by drugs which act 
through the central nervous system ( e.g. benzidrine and 
pyrifer ). 
(5) OTHER POINTS OF INTEREST. 
If ascorbic acid therapy is alleged to be beneficial 
in certain zymotic diseases, there immediately arises the 
question of how ascorbic acid can produce a beneficial effect. 
In this section it is proposed to touch briefly on certain 
physiological points. 
(A) The erythrocyte in relation to infectious diseases and 
to vitamin C. 
It is a well known fact that a hypochromic, microcytic 
anaemia occurs in typhoid, diphtheria, and " to some degree 
in most specific fevers " (221). Now, the administration 
of vitamin C not only cures the very similar anaemia found 
in scurvy (222 & 223), but also - according to a standard 
text -book on diseases of the blood (224) - causes a 
reticulocyte response in patients suffering from infections. 
Also, it is generally admitted that vitamin C is 
essential to normal erythropoiesis (225). 
iLThe leucocyte. 
A falling leucocyte count has long been recognised 
as a grave prognostic indication in such diseases as lobar 
pneumonia and cerebrospinal meningitis; and the introduction 
of sulphapyridine therapy has brought agranulocytosis 
into 
prominence / 
prominence. Hence, any drug which will prevent or cure 
leucopenia ( and, in particular, polymorphonuclear leuco- 
penia ) might find a place in the therapy of infectious 
diseases. 
That vitamin C is of value in leucopenia was first 
demonstrated by Schnetz (226), who found that, although 
'administration of the vitamin produces no leucocytosis in 
normal persons, such administration causes a definite rise 
in the leucocyte count in cases of leucopenia. Again, 
Kalk (227) has reported six cases of agranulocytosis 
successfully treated by daily injections of ascorbic acid. 
And Carrie (228) has claimed that vitamin C given during 
a course of X -ray therapy prevents an irritation leucopenia. 
) Antibodies, etc. 
The relationship of vitamin C to immunity processes 
is far from clear. It has been shown that there is a 
correlation between the concentration of ascorbic acid in 
the blood and complement in the serum (229); it has been 
proved that vitamin C increases the phagocytic properties 
of blood (178); and it has been claimed that the production 
of specific antibodies can be stimulated by intravenous 
injection of the vitamin (229). 
(D) Glycogenolysis. 
If the much favoured glucose drip has any value in 
severe infections, then a drug which influences the level 
of glucose in the blood must be important. It has been 
shown (230) that glycogen formation in the liver of hypo- 
-vitaminous rabbits is greatly stimulated by vitamin C; 
and in human beings it has been found (231) that the rise 
in blood sugar of a patient who took a hundred grammes of 
glucose by mouth was greater after high dosage with 
vitamins B and C than after no vitamin therapy. 
(E) Detoxicating function of vitamin C. 
The detoxicating action of ascorbic acid is well 
established: for example, Holmes and others (232) have 
demonstrated that it is beneficial in lead poisoning; Bise 
(233) and Lees (234) have found it useful in arsenical 
dermatitis; and Buckley and Sande have both recommended it 
for the treatment of cutaneous reactions following gold 
therapy. 
While these' findings are of significance in 
regard 
to syphilis, tuberculosis, and rheumatism, the action 
of 
ascorbic acid in preventing or reducing the toxic 
effects 
of the sulphonamide compounds is important in 
regard to 
such infections as cerebrospinal meningitis, tonsillitis 




action in preventing agranulocytosis due to these drugs, 
but - according to Dainow (235) - intravenous injections 
of the vitamin prevent or diminish all the other toxic 
effects of the sulphonamide compounds. 
There are other points in which the physiological 
actions of ascorbic acid suggest that it might have some 
value in infectious conditions - e.g. administration of 
the vitamin is followed by an increase in the lipase 
content of the blood (236), and a similar rise has been 
noted in the lipase content of the blood of tuberculous 
patients when they are progressing towards cure (237); 
however, the points already specified should be sufficient 
to demonstrate that there is an adequate physiological 
basis for clinical trials of ascorbic acid in infectious 
diseases. 
CONCLUSIONS FROM PART 1. 
(1). Although early workers used inaccurate methods for 
the estimation of vitamin C, and suggested different ( and 
more or less arbitrary ) standards of adequacy and normality, 
accurate methods of assay are now in existence, and - within 
fairly narrow limits - generally accepted standards have 
been devised for human requirements of the vitamin and for 
the vitamin C content of various body fluids and tissues. 
Hence, it should be possible to determine whether, in any 
particular disease, the bodily stores of the vitamin are 
reduced. 
(2). A survey of the published work shows that the bodily 
reserves of ascorbic acid are considerably reduced in 
Whooping Cough, Pneumonia, Diphtheria, Scarlet Fever, 
Rheumatic Fever, Pharyngitis, and Tuberculosis. For 
other infections evidence is lacking. 
(3). Since the tissues are partially depleted of vitamin 
C during the acute stage of these seven diseases, it 
follows logically that this depletion should be made good 
either by the administration of large doses of the vitamin 
during the acute stage or by the provision during conval- 
- escence of a diet rich in ascorbic acid; but ( except, 
perhaps, in tuberculosis, where the acute stage is of 
long 
duration ) it does not necessarily follow that the former 
of these alternatives is preferable to the latter. 
(4). Experiments on laboratory animals suggest 
that the 
administration of vitamin C may be beneficial in Whooping 
Cough, Pneumonia, Diphtheria and Tuberculosis. 
There is 
no evidence regarding other infections. 
(5) A consideration of some of the physiological 
functions 
of / 
of vitamin C makes it seem quite probable that administ- 
-ration of the vitamin will be useful in some of the more 
serious infections. 
(6). For most infectious diseases the efficacy of vitamin 
C therapy has still to be proved or disproved by clinical 
trial: the position is best summarised in the words of 
Harries and kitman ( Clinical Practice in Infectious 
Diseases, 1940, p.89 ), - " There is a loss of vitamin C 
in fevers, and it has been suggested that vitamins B and 
C have a therapeutic value, but this is not yet proved." 
In many infections ( e.g. Cerebrospinal Fever, Erysipelas, 
Scarlet Fever, Influenza, Leasles, Chicken -Pox, Small -Pox, 
Lumps, Glandular Fever, Undulant Fever, Typhus, etc. ) 
ascorbic acid does not appear to have been used; in other 
infections ( Enteric, Coryza, Tonsillitis, Pharyngitis, 
and kalaria ) isolated workers have reported favourably on 
the effect of the vitamin, but these reports still await 
confirmation or refutation. In only five infectious 
diseases has ascorbic acid been given a reasonable 
therapeutic trial, - .Rheumatic Fever ( if the term 
"infectious" can be stretched to cover this condition ), 
where vitamin C has proved valueless; Whooping Cough and 
Pneumonia, where it appears to be beneficial; and Diphtheria 




PART 2 - AN INVESTIGATION OF THE EFFECTS OF 
ASCORBIC ACID THERAPY IN CEETAIN INFECTIONS. 
In 1939 and 1940, for a period of about a year, the 
writer attempted to investigate the effects of ascorbic 
acid therapy as applied to infectious patients, practic- 
ally all of whom were in his own clinical charge, in 
Edinburgh City Hospital. The patients studied included 
108 cases of influenza, 148 cases of cerebrospinal fever, 
114 cases of diphtheria, 32 cases of streptococcal 
tonsillitis, 40 cases of scarlet fever, and 14 cases of 
post -influenzal pneumonia. In each disease the patients 
were divided into two comparable groups, which received 
the same diet and treatment, except that one group was 
given synthetic vitamin C. Subsequently, in 1941 and 
the early months of 1942, a few confirmatory experiments 
were carried out on patients under the writer's clinical 
charge at Kendray Isolation Hospital, Barnsley. The 
patients studied in these confirmatory experiments 
included 36 cases of diphtheria and 16 of cerebrospinal 
meningitis. 
The means taken to ensure that the groups were 
really comparable, and also to eliminate the effects of 
any unconscious personal bias on the part of the writer, 
are discussed in the reports on the separate diseases. 
(1) INFLII"r;NZA. 
The occurrence of an outbreak of influenza in two 
ships of the Navy while in port, and the consequent 
admission to hospital of 108 seamen, provided a golden 
opportunity for obtaining comparable groups. The 
patients, who were similar in sex, occupation, previous 
diet, previous general health ( the high standard 
required for the Senior Service ), etc., were transferred 
to hospital 24 - 48 hours after first reporting sick. 
They all suffered from a mild influenzal syndrome, 
- 
pyrexia, malaise, pharyngitis, some tracheitis, 
and 
vague pains; and they were obviously infected 
under very 
similar conditions. 
All patients were put to bed, and 
treated with Dover's 
powder and aspirin ( aá gr.X, bis ), throat 
gargles, and 
purgatives; all received identical diet; 
and every second 
case was given ascorbic acid orally, - 50 
mg. four times 
daily for two days. No additional treatment 
was given 
except in cases which developed complications. 
Two criteria have been used in 
comparing the two 
groups/ 
groups, - (a) the incidence of complications and relapses, 
and (b) the duration of illness from the date of reporting 
sick to the date of discharge from hospital. No question 
of personal bias arises over the discharging of the cases, 
because the discharges were arranged not by the writer but 
by a colleague ( the senior assistant medical officer at 
the hospital ) who was unaware of whether any particular 
patient had received vitamin C. 















1 21 98.6 8 
3 25 98.8 8 
54 2 97.6 8 
7 98.8 8 
9 43 98.7 8 
11 23 102. 8 
13 39 99. 10 
15 24 100.3 10 
17 24 99.1 10 
19 42 97.6 10 
21 21 99.1 10 
23 21 99.2 10 
25 43 100. 10 
27 39 98.2 10 
29 19 98.6 12 
31 22 100.8 13 
33 32 101.2 15 
35 24 98.2 9 
37 50 98. °. 
39 30 100.4, 
41 37 98.4 
43 20 100.4 
45 21 98.4 
497 23 100. 
51 
24 986 
53 49 99.2 
55 21 100.2 
57 34 99.6 
59 30 100.8 
61 25 98.6 
63 18 102. 
65 42 97.6 
67 21 97.8 





































2 ¡20 9. 8 
4 O0 00. 8 
6 2 s8.8 8 
8 9 :9. 8 
10 9 s9.2 8 
12 5 :8.8 10 
14 6 s8.8 10 
16 0 9. 10 
18 1 s7.6 10 
20 0 '9.2 12 
22 50 ' 9.2 12 
24 46 '9.1 12 
26 2 8. 11 
28 30 97.6 13 




it 9 98. 15 
38 19 101.8 15 
40 26 100. 9 
42 20 101. 9 
44 34 103. 17 
46 30 97.6 10 
48 26 98. 
10 
502 20 99.2 14 
54 30 98.6 15 
56 19 100. 20 
58 19 97.6 19 
60 23 100.2 13 
62 35 98. 23 
64 53 100.2 41 
66 20 99.8 { 
68 17 98. 10 
70 29 99. 8 
72 38 97.6 10 



























99. ! 11 
75 28 100.2 12 Bronchitis 76 29 97.6 9 - 
77 27 98. 8 78 35 97.9 9 - 
79 31 100. 10 80 24 103. 12 ;Bronchitis 
81 30 100.4. 8 82 19 99.4 7 - 

















89 23 99.4 10 90 26 97.6 8 - 
91 29 98.2 7 92 19 98. 7 - 
93 37 98.6 7 94 38 97.8 12 - 
95 23 98. 7 96 32 97.6 10 - 
97 39 99. 9 98 27 100. 8 - 
99 40 100.8 9 100 32 104.8 13 - 
10130 97.6 8 102 24 98. 10 - 
103 41 98.2 9 - 104 29 98.2 8 - 
105 39 97.6 8 106 34 98. 1.2 - 
107..20 98.5 12 - 1081 42 98.4 8 - 
Comparability of the Groups. 
The two series, vitamin C cases and controls, are 
similar in respect of occupation, previous diet, etc., but 
there are two points in which they are not necessarily 
identical: a larger number of initially severe cases might 
have chanced to fall into one series; and the proportion of 
elderly men - who might be expected to recover more slowly 
- might not be equal in the two series. 
Perhaps the best single criterion of initial severity 
is the degree of pyrexia at the time of admission to 
hospital. Judged by this standard the groups are similar, 
with a very slight bias in favour of the controls: 
Number of patients of 
Initial Temperature Group (A) Group (B) 
98.5° and under 19 24 
98.6 - 99.50 16 17 
99.6 -100.5° 12 6 
100.6° and over 7 7 
54 54. 
An attempt to divide the patients, when first examined,into 
kild, koderate and Severe cases shows even less disparity 
between the groups: 
Group (A) Group (B) 
Number of mild cases 11 14 
" " moderate " 32 31 
" " severe " 11 9 
As for age- distribution, there is a slight preponderance 
of/ 
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of older men in the vitamin C group and of young lads in 
the control group: 
Number of patients from 
Age. Group (A) Group (B). 
17 - 21 years. 11 17 
22 - 39 " 32 31 
40 years and over 11 6 
However, study of the individual cases shows that there 
is no justification for the view that older men would 
recover more slowly: of the 11 older men in Group (A), 
not a single one had a relapse or developed a complic- 
-ation, and the average duration of their illness was 
actually a little less than the average duration in the 
whole group. Equally, there is no evidence to suggest 
that young lads were more severely affected: in the 17 
youths of Group (B) the incidence of complications or 
relapses ( 29.4`¡ ) is almost identical with the incidence 
in the entire group ( 29.6% ); and the average duration 
of illness among the youths was a shade less than the 
average for the whole group. Moreover, the average 
duration of illness for each series of 54 patients 
( 10.2 days for the vitamin C cases and 11.78 days for 
the controls ) corresponds very closely with the average 
for the 22 - 39 years age -group ( 10.0 days for the 
vitamin C cases and 11.58 days for the controls). 
The two groups, then, may legitimately be compared. 
Comparison of the Groups in respect of Complications and 
Relapses. 
In the 54 cases treated with vitamin C there were 4 
relapses and 3 complications ( one case of pneumonia and 
two of bronchitis ); of the 54 controls 9 had relapses 
and 7 developed complications ( two cases of pneumonia, 
two of gastritis, and one each of otitis media, sinusitis 
and bronchitis ). 
The probability of an uncomplicated convalescence 
was therefore 87.04 % in the vitamin C cases and 70.37 
in the controls. The standard error of the probabilities 
/ 87.04 x 12.96 70.37 x 29.63 
is or 
+ 7.71 ._ 
_ 54 54 
Hence the actual difference between the probabilities, 
16.67 %, is 2.16 times the standard error. 
Comparison / 
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Comparison of the Groups in respect of Duration of Illness. 
The main points can be summarised thus : - 



















Number of patients from 














Total days of illness 551 
Average duration of illness 10.2 days 
kedian " n n 9 n 
Lower Quartile 10 






















Standard error of difference = ±0.95 
Actual difference of means = 1.58, or 
1.66 times standard error. 
Discussion. 
In the 54 cases of influenza treated with ascorbic 
acid the incidence of complications and relapses was 
lower, and the average duration of illness was less, than 
in the 54 controls; but the differences were a little 
below the lower limit acceptable for statistical signif- 
-icance. The experiment, then, does not permit of the 
drawing of definite conclusions. The probability is that 
oral administration of 400 mg. of vitamin C to a case of 
a fairly mild type of influenza does shorten the illness 
and reduce the risk of complications, but there is a 
possibility that the apparent beneficial results of vitamin 
C therapy are really due to chance. 
The dosage of vitamin C employed was based on Falke's 
finding that an additional 100 mg. were required daily 
during pyrexia. As patients were admitted to hospital 
within 48 hours of the onset of their illness, and as 
observation of earlier cases ( not included in the series ) 
had shown that they remained febrile for - on the average - 
about 2 days after admission, a dosage of 400 mg. in two 
days/ 
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days was selected. It was felt, however, that an attempt 
should be made to ascertain whether the dosage given was 
really adequate. For this purpose plasma and blood estim- 
-ations seemed unsatisfactory, since - as has been pointed 
out earlier - ingestion of large amounts of the vitamin 
may cause a temporary rise in the blood concentration at a 
time when the tissues are still partially depleted; the 
use of a saturation test was ruled out by the nature of the 
experiment; and Neiklejohn and Stewart had not yet devised 
their enzyme test . In default, therefore, of a better 
method, the dichlorophenol- indophenol test of urinary 
excretion was employed. 
Excretion of Vitamin C in Influenza. 
(a) Controls. The urinary concentration and total 
excretion of 32 of the control cases was estimated during 
their first three days in hospital. In spite of the fact 
that these patients received a little aspirin, a drug that 
increases the urinary output of ascorbic acid, the output 
was uniformly low, as the following summary will reveal: 
Concentration Number of patients. 
in mg. /cc. 1st. day. 2nd. day. 3rd. day. 
Under .005 6 7 7 
.005 -.006 12 11 10 
.006 -.009 10 11 10 
Over .009 4 3 3 
32 32 30 
Total excretion 
in mg. 
Under 5 10 11 12 
5. - 6 6 6 
6 
6.1 - 10 8 7 7 
Over 10 8 8 5 
32 32 30 
* Two specimens lost. 
The highest concentration recorded for any patient 
on any 
of the three days was .0099 mg. /cc., a dangerously 
low 
concentration. The lowest concentration 
was .0037 mg. /cc., 
and the average was .0064, with 0 of 0.20. The highest 
total excretion on any day was 14.4 mg., 
the smallest was 
3.6 mg., and the mean was 7.24 mg. 
(b) Cases given 400 mg. of vitamin 
C. The urinary 
concentration of 44 of the treated cases 
was estimated after 
one complete day in hospital, - i.e. 
after they had received 
200 mg. of ascorbic acid. The concentration 
was found to 
range from .003 to .0125 mg. /cc., 
with a mean of .0083 mg /cc. 
The total excretion during the 
first complete day in hosp- 
-ital varied between 4.6 and 19.2 mg, 
with a mean of 8.82 mg. 
The estimations were_repeated 
on 24 of the patients 
after / 
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after they had received the full 400 mg. The concentration 
now ranged from .0071 to .015 mg. /cc., with a mean of .0111 
mg. /cc.; and the total excretion ranged from 9.9 to 22.4 mg., 
with an average of 16.6 mg. 
It appears, then, that the vitamin C excretion of the 
controls was very low indeed; that the first 200 mg. of the 
vitamin given to the treated cases was practically all 
retained by the tissues, and caused very little increase in 
the excretion; and that the second 200 mg. resulted in an 
appreciable rise in the excretion, but that even this rise 
did not bring the excretion to the level of normality. 
These findings made it clear that 400 mg. of ascorbic 
acid were insufficient to remedy the state of hypovitaminosis 
present in influenza. Since influenza is not often treated 
in a hospital for infectious diseases, no opportunity 
occurred for repeating the experiment with larger dosage of 
the vitamin. For subsequent experiments on other infections, 
however, a larger dosage was employed. 
(2) CEREBROSPINAL MFNINGITIS. 
The 1940 epidemic of cerebrospinal fever afforded 
opportunity for the investigation on a considerable scale 
of the possible effects of ascorbic acid therapy. In view 
both of the rapidity which often characterises a toxic case 
of " spotted fever " and of the prevalence of symptoms of 
gastro- intestinal upset ( one of the undesirable effects 
of sulphapyridine ), it was deemed desirable to investigate 
separately the effects of oral' and parenteral administration 
of the vitamin. 
Experiment I - Oral administration of vitamin C. 
For this investigation 120 consecutively admitted 
cases of cerebrospinal meningitis were divided - on the 
alternate case principle - into two groups of 60. Members 
of Group (A) - i.e. every alternate case admitted during 
the period - were offered vitamin C in tablet form for 
four days, the dosage for adults being 50 mg. thrice daily 
( i.e. 600 mg. in all ), while children between the ages 
of two and twelve years were given 50 mg. twice daily (i.e. 
400 mg. in all ), and infants under two years received 
25 mg. twice daily ( or 200 mg. in all). Members of 
Group (B) were given no supplement of vitamin C, but, 
in 
all other respects, received the same treatment ( standard 
dosage of sulphapyridine, etc.) and the same diet. 
In all cases the criterion of diagnosis was 
the 
presence of Gram negative diplococci in the 
cerebrospinal 
fluid of a patient who showed clinical signs 
of meningitis. 
As/ 
As many of the patients in Group (A) were too sick 
to tolerate vitamin C given by mouth, and as exclusion of 
these patients without any corresponding exclusions from 
Group (B) would obviously invalidate any conclusions, it 
is necessary to select a line of demarcation equally 
applicable to both groups. Since ability to tolerate 
sulphapyridine by the oral route obviously implies ability 
to retain vitamin C given by mouth ( although the converse 
is not true ), it seems to be the obvious choice for the 
line of demarcation. 
The patients excluded on the ground of inability to 
tolerate sulphapyridine given by the oral route include 
18 from Group (A) and 14 from Group (B); we are therefore 
left with 42 cases treated with ascorbic acid, and 46 
controls. 
Details of individual cases are given in tables II 
and III. 
Table II. 
Cases of meningitis treated with ascorbic acid. 
No. Sex. Age !Complications. Duration2ofdillness. 
1 F 17 yrs. - 
2 L 8 l Arthritis, transient 30 " 
3 L 18 
I - 29 " 
L. 
8/12 Died 44 hrs. after admission. 
L 23 
- 28 days 
6 L: 1 6/12 - 
36 'i 
7 L 9/12 - 
32 " 
56 Died 74 hrs. after admission. 
3 Ataxia, transient 54 days 




12 F 28 
Arthritis, transient 38 " 
II 
L 1 7/12 - 
44 
29 It 
L 24 29 it 
16 
" 15 L_ 10 
Leg pains, lasted -
F 28 " 
17 L 28 
- 27 
27 II 
18 F 5 
I 
29 ti 






Arthritis, transient 53 " 
21 F 46 
ill 




Yi 1/12 - It 
L 11/12 - 
29 
29 " 
26 F 30 - 




M 6 - 
27 
29 ii 
29 U 21 - 
( Continued on next 
page ) 
* Discharge delayed through 
intercurrent varicella. 








Table II (continued ). 
Age in !Complications. Duration of illness& 
years. in days 
50 - 28 
31 Ivi 1 9/12 - 27 
32 Lí 20 - I 30 
33 F 22 - I 31 
34 IVí 24 Leg pains, lasted 29 
35 F 7/12 - ! 27 
36 L 3 - 36 
37 F 18 - 28 
38 Ii 27 - 29 
39 L 17 - 28 
40 Li 33 Ataxia, lasted 27 
41 Li 38 - 26 



















used as controls. 
Complications. Duration of illness 
in days. 
24 
Leg pains, lasted 33 
Nuchal rigidity,lasted* 27 
4 F 4 28 
5 r 9/12 
6 Lí 20 Ataxia, lasted 28 
7 1 6 28 


















17 F 1 4/12 Belapse, 
transient 37 
18 F 2 I Died 
on 64th. day (hydrocephalus) 
19 F 
20 18 Tachycardia, 
lasted 47 





25 IVi 27 
Arthritis, lasted 38 
26 IVi 










* Died later of another disease; post 
mortem showed old 
meningeal adhesions 
° Discharge postponed because 

















used as controls. 
Complications. 1Duration of illness, 
in days. 
Relapse, transient 44 
- 29 
32 M 65 Died 59 hrs. after admission. 
33 M 3/12 - 31 
34 F 3/12 Died on 5th. day in hospital. 
35 M 5 - 29 
36 M 2 2/12 - 28 
37 M 31 - 26 
38 F 9/365 - 34 
39 M 25 - 25 
40 Ivi 9 - 28 
41 F 13 - 27 
42 M 52 Died on 6th. day in hospital. 
43 F 4 Died 16 hrs. after admission. 
44 F 3 Died 23 hrs. after admission. 
45 M 44 Arthritis, lasted 44 
46 M 2 Died on 10th. day in hospital. 
( N.B. The word "lasting", as used in tables II and III, 
means that the particular complication or sequel so described 
was still present when the patient left hospital; it does 
not necessarily imply permanence.) 
Comparison of the Groups. 
Some of the main points regarding the two groups may 
be summarised thus: - 
Group (A) 
( Vitamin C ) 
1. Total patients. 
No. of cases 42 
Deaths 2 ( 4.76 %) 
Lasting sequelae 4 ( 9.52 %) 
Transient complications 5 (11.9 %) 




7 (15.22 %) 
7 (15.22%) 
5 (10.87¡x) 
27 (58.7 %) 
Mean duration in survivers31.2 days 
2. Patients aged less 
than three years. 
30.8 days. 
No. of cases 9 16 
Depths 1 (11.11 %) 3 (18.75 %) 
Lasting sequelae 0 1 ( 6.25 %) 
Transient complications 0 2 (12.5 %) 
Recoveries without " 8 (88.89 %) 10 (62.5 %) 
3. Patients aged more 
than 45 years. 
No. of cases 2 4 
Deaths 1 (50 % ) 
2 (50 %) 
Lasting sequelae 0 
1 (25 %) 
Recoveries without complic'n. 1 (50 %) 
1 (25 %). 
4/ 
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4. Patients aged 3 - 45 





hecoveries without " 
Group (A). Group (B). 
31 26 
0 2 ( 7.69A )
4 (12.9 jo) 5 (19.23¡) 
5 (16.13;0) 3 (11.500) 
22 (70.97;) 16 (61.54;4. 
A direct comparison of the 42 patients of Group (A) 
with the 46 controls of Group (B) would give the erroneous 
impression that, while the average duration of illness in 
survivers is almost identical in the two groups and while 
the difference in incidence of complications is slight, 
there is a difference in the probability of death which, 
although not actually statistically significant ( it is 
1.68 times the standard error of the difference ), is yet 
highly suggestive. Such an impression would be quite 
unjustified, because the control group is handicapped by 
its unduly large proportion of infants and elderly persons, 
- the very sections of the community in which the vast 
majority of deaths from meningococcal meningitis occur. 
Since the disparity of the age- distributions makes 
direct comparison of the two groups utterly valueless, we 
are compelled either to compare the two series age -group 
by age-group ( in which case the differences in incidence 
of sequelae and in percentage of deaths will be found to 
be constantly in favour of the patients who received 
vitamin C. but will also be found to be invariably very 
far below the level of significance ), or to try to obtain 
a picture of the real differences between the groups by 
standardising the death rates and complication rates. 
Since it is immaterial what population we take as 
our standard, it is convenient to take the age- distribution 
of Group (B) as the standard - so that the rates for that 
Group need no alteration - and to calculate the rates that 
would obtain in Group (A) if the number of patients in 
each age -group were raised or lowered to that of the 
corresponding age -group of Group (B). Standardisation 
reveals that, although the differences are certainly in 
favour of Group (A), these differences are very far from 
being significant: - 
Standardised death rate of Group (A) = 8.21;0. 
( B ) = 15.22;i0. 
Difference = 7.01 ¡a, or 1.05 times the 
standard error of the difference ( 16.67) 
Standardised complicat' rate of Group (A)= 16.43 ¡'. 
n H " " " (B)= 26.09 ¡0. 
Difference = 10.34 ¡0, or 1.22 times the 
standard error of the difference ( ±8.47). 
EL.perirnent / 
; xperiment II (al_ - Parenteral administration of vitamin 
C to toxic cases of cerebrospinal meningitis. 
While Experiment I ( on oral therapy with ascorbic 
acid ) was in progress it was felt that some of the patients 
who were unable to tolerate drugs by mouth might be utilised 
for investigation of the effects of parenteral administration 
of the vitamin. Accordingly,, all those patients of the 
original Group (A) who - after 24 hours in hospital - were 
still unable to tolerate sulphapyridine orally were given 
an intramuscular injection of 500 mg. of ascorbic acid, 
approximately 24 hours after admission to hospital; and 
those of the Group (B) patients who, after a similar lapse 
of time, still required parenteral administration of 
sulphapyridine were regarded as controls. 
The 500 mg. of the vitamin given intramuscularly were, 
of course, additional to any portion of the first day's 
oral dosage that the patients managed to retain. 
As was stated earlier, 32 out of 120 cases had to be 
excluded from Experiment I on the ground of inability to 
tolerate drugs by mouth. The first 7 of these 32 were 
either convalescent or dead before Experiment II (a) was 
commenced. The remaining 25 - twelve from Group (A) and 
thirteen from Group (B) - formed the material for the 
experiment. 
Twenty -five cases are too few to permit of the drawing 
of conclusions, but - as these cases will be used later in 
conjunction with the cases of Experiment II (b) - details 
of the 25 are given in tables IV and V. 
Table IV. 
Toxic cases of meningitis given vitamin C parenterally. 
No.Sex. e hash? Grades Complications. Duration 
of 
in l illness 
in days. 
rs. 
1 r 30 Yes + ++ Neuritis, 
lasted 30 
2 Ii 23 No + ++ 
- ' 34 
3 Li 63 No + ++ 
Died 61 hrs. afte30admission. 
4 Iv: 44 Yes + ++ - 
' 
{ 30 
5 1 0 No ++ 29 
6 Ì. 4 Yes + ++ - 27 
7 Iv: 5 Yes + ++ 
- 
8 F 42 No T 
Died 55 hrs. after admission. 
9 m 15 No ++ 
- 27 
10 F 6 Yes + + ++ , Died 
32 hrs. after Admission. 
11 F p5 Yes '+ ++ Neuritis, 
lasted 23P 
12 L 6 INo + ++ - 
31 
Table / 
° Patient left on her own responsibility. 
* Grades of initial severity: + = gild; 
++ = Average; 

















Toxic cases of meningitis used as controls. Age in Rash ?!Grade. Complications.. Duration of 
years. i illness in days. 5 Yes I + ++ Died 65 hrs. after admission. 
72 No ; ++ Died 61 hrs. after admission. 
30 No + Neuritis, transient 28 
22 No ' + ++ Died 53 hrs. after admission. 
34 No ++ ;Arthritis, transient 28 ' 
30 No ++ - 26 
32 No + ++ - 27 
31 No + ++ - 30 
++ - 28 
+ ++ Died 64 hrs. after admission. 
+ + ++ Died 45 hrs. after admission. 
+ ++ Deafness, lasted 44 






Comparison of Groups. 
Some of 
groups may be 
the main points of difference 
expressed thus: - 
Toxic cases treated 






Average duration of 
illness in survivers 
between the two 
Toxic Controls. 
12 13 
3 (25. %) 6 (46.15%) 
2 (16.67%) 3 (23.08 %) 
7 (58.33%) 4 (30.77%) 
29.75 days. 30.14 days. 
To dispose in advance'of any suggestion that the 
mortality of the control group was so unusually high as to 
render that group unsuitable for use in a comparison, it 
must be emphasised that these twenty -five patients were 
not ordinary cases of cerebrospinal meningitis, but cases 
selected on the ground of being too ill to tolerate 
sulphapyridine orally, - i.e. selected from the group in 
which the majority of deaths occur. 
No patient in these two groups was able to take 
sulphapyridine by mouth; a petechial rash ( which is a 
rough indication of extent of septicaemia ) was present in 
six of the vitamin C cases as compared with four of the 
controls; clinical division of the patients ( by the 
writer ) into various grades of initial severity suggested 
that the vitamin C cases were, on the average, a shade 
more toxic on admission; and there was little difference 
in the age- distributions of the two groups. In these 
circumstances it was felt that the reduction in mortality 
rate in the vitamin C cases was - by comparison with the 
controls - sufficiently marked to make a further investig- 
ation of the effects of parenterally administered ascorbic 
acid/ 
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acid eminently desirable. 
Experiment II (b) - Parenteral administration of vitamin C. 
The experiments previously described were performed on 
one hundred and twenty consecutive cases of cerebrospinal 
meningitis. Por the next thirty cases admitted to hospital 
it was decided to give each alternate patient ascorbic acid 
in large amounts, intramuscularly, the dosage chosen being 
500 mg. daily for three days for an adult or a child over the 
age of five years, and half that daily quantity for younger 
children. Unfortunately, two cases of pneumococcal mening- 
-itis were included in error, - a result of treatment being 
started as soon as lumbar puncture had revealed a turbid 
cerebrospinal fluid. 
Details of individual cases are given in tables VI and 
VII. 
Table VI. 
Cases of meningitis given vitamin C parenterally. 
No.Sex.Age in 
;years. 
Rash? Grade. Complications. Duration of 
illness in days. 
1 Bú 5 Yes + ++ 28 
2 F 8 Yes + ++ 28 
3 k ;18 Yes ++++ 31 
4 ( Prieumococcal, - excluded.) 
5 L j 5/12 'Yes ;++ 28 
6 F 25 No +++ 26 
7 F 9/12 ;No 
26 
8 k 4 .No ;++ 
27 
9 Iu. 20 :Yes H+ 27 
10 };. :14 Yes ;+++ 
ONO 28 
11 h' 14 .No ¡+++ 
32 
12 ( rneumococcá.l, = excluded.) 
13 k 21 No ! ++ 
27 
14 F 1 No ++ 
40 













Sex.lAge in Rash ?: 
rears. 
k 27 No 
F 6/12 No 
1 ' 2 Yes 
F. 42 No 
F. 17 No 
L. 14 Yes 
L. 3 Yes 




meningitis used as controls. 
Grade.; Complications.) Duration 
of 
i 
illness in days. 





Died 70 hrs. after admission. 
++ 
+ ++ ;Arthritis, lasting 
+ ++ Neuritis, transient 
++ - 






* Transferred to another hospital 
for treatment of arthritis. 
Table VII (continued). 
No.SexiAge in!Rash ?;Grade. Complications.; Duration of 
;years. illness in days. 
10 M 1 2 Yes + ++ - 36 
11 M ; 5/12 No ++ - 31 
12 F ¡20 No ++ - 25 
13 M 152 Yes + ++ Died on 6th. day in hospital. 
14 M 
1 
5 No ++ - 30 
15 M ' 6/12 No + + ++ Died 10 hrs. after admission. 
The outstanding feature of these cases is, of course, 
the absence of any deaths, complications, or sequelae in 
the group treated with intramuscular injections of ascorbic 
acid. 
Commparabilit_of the Groups. 
An attempt by the writer to classify the patients 
immediately after admission into various grades of initial 
severity showed little disparity between the two groups: 
one member of each group was regarded as " moribund ", seven 
of each group were classed as " severe ", while five vitamin 
C cases and seven controls were judged to be " moderate ". 
hashes were present in six members of each group. The sex 
distribution was similar, - 8 males and 5 females in the 
vitamin C group, and 9 males and 6 females in the controls. 
Apart from the fact that the control group contained two 
patients in late middle -age, the age- distributions were 
much the same two 
Age in years. Vitamin C cases. Controls. 
Under 2 3 4 
2 - 10 3 3 
11 - 20 5 4 
21 - 39 2 2 
40 - 55 0 2 
13. 15. 
60 
Comparison of the Groups. 
The two series of cases are here compared in respect 
of deaths, complications, and duration of illness. With 
regard to the last of these points, it should be mentioned 
that the discharging of the patients was in the hands not 
of the writer but of a colleague who did not know to which 
group any particular patient belonged. 
The main features may be summarised thus: - 
Vitamin C cases. Controls. 
Total cases 13 15 
Deaths 0 3 (20 
¡0) 




9 (60 ¡,) 
Average duration of illness 
in survivers 29.08 days 
31.27 days. 
( In calculating the average duration of 
illness, the patient - 
Control / 
61 
Control Group, No. 7 - who was transferred to another hosp- ital for treatment of a complication, has been excluded.) 
It was hardly to be expected that such small numbers 
would provide differences large enough to be statistically 
significant. Yet the standard error of the probabilities 
of recovery without complications is 12.65, so that the 
actual difference - 40 % - is more than three times the 
standard error. 
If we add together the figures for Experiments II (a) 
and II (b), we have: 
Parenteral vitamin C cases. Controls. 
Total cases 25 28 
Deaths 3 ( 12. %) 9 (32.14 %) 
Complications 2 ( 8. %) 6 (21.43 %) 
Recoveries without 
complications 20 ( 80. %) 13 (46.43 %). 
The difference between the rates for recoveries without 
any complication is 33.57 %, or 2.714 times the standard 
error of ± 12.37. 
As for the death rates, the actual difference is a 
fraction under twice the standard error, but it is obvious 
that, in Experiment II (a), where the ascorbic acid was not 
given until the patient had been in hospital for 24 hours, 
it could not reasonably be expected to prevent the death of 
one patient who expired early on her second day in hospital. 
Exclusion of all patients who died within 36 hours of their 
admission would give a death rate for the 
of 2/24, or 8.33 %, as against 8/27, or 
controls; and the difference - 21.3 % - 
the standard error. 
Equally informative is a division 
into age- groups: 
Ratio of deaths to cases. 
vitamin C cases 
29.63 %, for the 
is well over twice 
of these 53 cases 
Ratio of complications 
to survivers. 
Age. Vitamin C cases. Controls. Vit. C cases. Controls. 
Under 1 year 0/2 2/4 0/2 0/2 
1 - 3 years 0/1 1/4 0/1 1/3 
4 - 19 H 2/12 2/7 0 /l0 1/5 
20 - 39 " 0/8 1/9 2/8 3/8 
40 years and over 1/2 3/4 0/1 1/1 
Total 3/2f) 9/28 2/22 6/19. 
In not a single age -group does the advantage rest with the 
controls. 
Comparison of the entire 148 cases of meningitis. 




(a) Early controls, - i.e. the 60 patients who were origin - 
-ally taken as controls for Experiment I. ( 46 of these 
were actually used as controls for Experiment I, the 
remaining 14 being too sick to tolerate drugs orally; and 
the last 13 of these sick patients were used as controls 
for Experiment II (a).) 
(b) Late controls, - i.e. the 15 patients used as controls 
for Experiment II (b). ( The 75 controls represent every 
alternate case admitted during the period of the experiments). 
(c) Early " oral " cases, - i.e. patients who were offered 
ascorbic acid by mouth and were not given any ascorbic acid 
parenterally. ( This group includes all of the 60 cases 
originally taken for Experiment I, except the 12 who 
subsequently received vitamin C intramuscularly. Tor 
comparative purposes this group is therefore in a position 
of favourable bias, in that 12 very sick patients have 
been excluded from it and placed in a separate category.) 
(d) 500 mg. group, - i.e. the 12 toxic cases, too sick to 
tolerate sulphapyridine orally, that received single 
injections of vitamin C. ( For comparative purposes this 
group is under a handicap: it consisted entirely of selected 
toxic cases.) 
(e) 1500 mg. group, - i.e. the 13 cases used in Experiment 
II (b). 
The five groups can be summarised thus : - 














" oral " 
cases. 


































Total. 148 7 20 29 
92 (62.16A. 
In the early controls and the late 
controls the 
death rates are almost identical ( 21.67 % 
and 20. % 
respectively ), and the incidence of complications 
does 
not differ greatly. It appears, then, 
that during the 
portion of the epidemic under consideration 
the disease 
did not undergo any marked change in its 
severity. Hence 
there is no valid reason why the Group (e) 
cases should 




will be made in respect of mortality rates, incidence of 
complications, and percentage of recoveries without any 
complication. 
(1) Death rates. Among the seventy -five controls 
the probability of dying is 21.3 with a standard error 
of _ 4.56 . In the patients who received 1500 mg. of vit- 
-amin C the probability of dying is 0 ¡o. The difference 
is, therefore, definitely significant. Even if we exclude 
the three controls who died early ( on the ground that no 
drug could benefit such cases ), the difference between 
the mortality rates of the 1500 mg. patients and of the 
controls remains statistically significant. 
(2) Incidence of complications. Among the controls 
the incidence of complications is 24 ¡ó, with a standard 
error of ± 4.93 . Again, the difference in the 1500 group 
- where the incidence is 0 % - is significant. 
(3) Probability of recovery without any complications. 
In the controls the probability of an uncomplicated conval- 
-escence is 54.67 ¡ with a standard error of 5.75. The 
probability in the 150G mg. group is 100 r, and the differ - 
-ence is definitely significant. 
Finally, let us compare the incidence of uncomplicated 
convalescences in the 25 patients who received vitamin C 
parenterally and in the other 123 patients. The dice, in 
this comparison, are weighted against the 25 parenteral 
cases, because twelve of them ( the Group (d) cases ) were 
not unselected cases, but toxic cases unable to take drugs 
orally. The incidence of uncomplicated recoveries in the 
123 patients who received no ascorbic acid parenterally is 
58.54 p, and the corresponding rate in the 25 patients who 
received one or more injections of the vitamin is 80 
standard error of the difference is 
/80 Y 20 ;" 58.54 x 41.46 
25 123 
or ± 9.15 - So the actual 
difference, 21.46 ¡ó, is - even in this weighted comparison 
- more than twice the standard error. 
Every single comparison, then, emphasises the marked 
differences between cases treated with intramuscular 
injections of vitamin C and controls who received no such 
injections. 
Experiment III - Confirmatory., 
A brief confirmatory experiment was conducted 
at 
Kendray Isolation Hospital, Barnsley, every alternate case 
admitted/ 
64 
admitted with cerebrospinal meningitis receiving daily 
injections of 500 mg. of ascorbic acid during the first 
three days in hospital. Except in case No. 8, the first 
injection was always given intravenously; the second and 
third injections in all cases, and the first injection in 
case 8, were given intramuscularly. The criterion of 
diagnosis and the general treatment were exactly the same 
as in the Edinburgh cases. 
Details of individual cases are given in table VIII, 
but " Duration of illness " is deliberately omitted, because 
the discharging of the patients was in the hands of the 
writer who might be guilty of unconscious bias. 
Table VIII. 




Sex. Age in , sash? Grade.; Complications. 
years. 
Al 1500 mg. F 11 No ++ 
A2 1500 mg. I 13 No + ++ 
A3 1000 mg. E 2 No + - 
A4 1500 mg. F 39 :Yes + ++ 
AS 1500 mg. F 7 No + ++ Strabismus, transient. 
A6 1500 mg. F 21 No + ++ - 
A7 1500 mg. F 36 : Yes + ++ Haematuria, transient. 
A8 1000 mg. bi 1 1/12 Yes ++ 
Bl Nil. L : 29 No ++ Otitis, transient. 
B2 " 5 Yes ++ Neuritis, lasted. 







1 1/12 Yes ++ 









20 No + ++ Deafness, lasted. 
28 Yes ++ Deafness, lasted. 
1 9/12 No + - 
Comparison of the groups., 
These two short series, comparable enough in respect 
of initial severity, are - although Group B contains one 
infant appreciably younger than the youngest child in Group 
A - not dissimilar in age- distribution. In the absence of 
any evidence that the meningococcus is more toxic to males 
( who predominate in Group B ) than to females, the groups 
may legitimately be compared. 
The main points of difference are: - 
Vitamin C cases. Controls. 




Transient complications 2 
1 
lasting sequelae 








These cases are not sufficiently numerous to be 
significant by themselves: for example, the difference in 
the probabilities of uncomplicated convalescence is only 
1.63 times the standard error of the difference. Since, 
however, the observed results in these cases accord with 
the findings obtained in the Edinburgh cases, they afford 
very valuable corroborative evidence. 
Their value does not lie in the fact that the 
ascorbic acid cases and the controls can be grouped with 
their respective Edinburgh counterparts to form two series 
which aizfer significantly. It lies, rather, in the fact 
that the presence of similar findings in a second series 
of cases virtually eliminates the possibility of chance 
playing a part. So long as we have only one series of 
cases and controls, the differences - even though they 
satisfy all the criteria of statistical significance - 
might conceivably be due to some freak of chance: after 
all, the generally accepted criterion of a " significant " 
difference - a magnitude greater than two and a half times 
6 - simply means that there is less than one chance in a 
hundred that the difference is coincidental. But it would 
be in the nature of a miracle if the very freak of chance 
that occurred in one series were to be repeated in the 
next series. - To adopt the parlance of the race -course, 
if the odds against the Edinburgh results ( considered by 
themselves ) being due to chance are estimated at about 
150 to 1, and if the odds against the Barnsley results 
( considered alone ) being due to chance are estimated at 
about 75 to 1, then the odds against the results of the 
two series ( considered together ) being due to chance will 
be in the neighbourhood of 11,000 to 1. 
Conclusions. 
The value of parenteral administration of vitamin 
C as an adjuvant to the sulphapyridine treatment of 
cerebrospinal meningitis is proved beyond shadow of doubt. 
Cases so treated showed a very marked decline, as compared 
with appropriate controls, both in the percentage of deaths 
and in the incidence of complications and sequelae. 
On the other hand, oral administration of the 
vitamin is often impracticable owing to the alimentary 
upset induced by sulphapyridine; and even in those cases 
of meningitis that can tolerate oral medication the 
evidence in favour of administration of ascorbic acid by 
mouth is very indefinite: cases so treated appeared to 
show a slight reduction in the frequency of complications 
and in the average duration of illness, but these apparent 
reductions were so slight that a very extensive experiment 
would be necessary before it could be ascertained whether 
they were significant or due to chance. 
(3)/ 
L3) STREPTOCOCCAL TONSILLITIS AND SCARLET FEVER. 
.á) Tonsillitis. 
During the investigation of ascorbic acid therapy 
in diphtheria ( vide infra ), a number of patients, who 
were at first placed either in the group of " Mild cases 
of diphtheria treated with vitamin C " or in the group 
of " gild cases of diphtheria used as controls ", had to 
be excluded after laboratory examination had revealed 
that the only pathogenic organism present in throat swabs 
was Str. Pyogenes. As these cases accumulated, it was 
felt that they might be used for an investigation of the 
effects of vitamin C in tonsillitis. 
Accordingly, 32 cases of streptococcal tonsillitis 
were studied, the criterion of diagnosis accepted being 
an inflamed throat from which haemolytic streptococci 
were cultured. Some of these 32 cases were, as mentioned 
above, originally classed as " diphtheria ", while others 
were recognised from the beginning as tonsillitis. Such 
of the patients as originally fell into the category of 
"Mild cases of diphtheria treated with vitamin C " had 
invariably begun to receive ascorbic acid before they 
were recognised as cases of tonsillitis. Hence the use 
of the alternate case method was impracticable. 
In all, 16 unselected cases were studied as controls, 
and 16 unselected cases were treated with vitamin C, the 
dosage employed being 100 mg. daily for eight days for 
adults and children over the age of eight years, and 50 
mg. daily for younger children. Since none of the cases 
developed complications, comparison was limited to two 
points, - the duration of tonsillar inflammation, and the 
duration of stay in hospital. ( " Duration of stay in 
hospital " was chosen, rather than " duration of illness ", 
because with young children the history of onset tends to 
be unreliable.) 
Details of the individual patients are given 
in tables 
IX and X. 
Table IX. 
Cases of streptococcal tonsillitis treated 
No. Sex. Age in Duration of inflammation 
years. of tonsils, in days. 
1 F 8 
2 L 6 
3 IL 3 











































Table IX (continued). 
Sex. ;Age in Duration of inflammation Length of stay in years. of tonsils, in days. 
1 hospital, in days. F 2 1 10 
k 4 
21 





k 9 9 
14 
1 F 14 ` 7 15 
i 
F 2 10 
k 23 
17 
10 16 . 
Table X. 
Cases of streptococcal tonsillitis used as controls. 
No.!Sex.,Age in ,Zuration of inflammation Length of stay in 
years. of tonsils, in days. hospital, in days. 
1 k 22 12 23 
2 F 27 7 12 
3 I 2 17 ' 20 
4 ; F 44 7 ` 10 
5 F 20 7 16 
6 ' &: 9 7 10 
7 4 12 15 
8 F 30 8 17 
9 F ' 6 3 ' 8 
10 F 18 10 13 
11 ; k 25 10 15 
12 k ; 6 21 26 
13 
' F 3 14 23 
14 9 10 15 
15 1 17 10 17 
16 Li 6 12 16 . 
The main points regarding the two groups may be 
summarised as follows: 
Vitamin C group. Controls. 
kedian duration of inflammation 8 days. 10 days. 
Average 9.0 " 10.44 
cr of " " " ±3.29 
± 4.23 
kedian " " hospitalisation 14.5 days. 15.5 days. 
Average " " " 14.75 " 16.0 " 
cr of " " " ± 3.76 ± 4.86 
Actual difference in average duration of inflammation 
= 1.44 
days; and standard error of difference = 1-1.34 
Actual difference in average duration of hospitalisation 
= 1.25 days; and S. E. Difference = ±1.54 
Hence, although the average duration 
was less in cases 
of tonsillitis treated with vitamin C than in comparable 
controls, the application of statistical 
methods shows that 
the / 
0t5 
the differences were far below the level of significance. 
.02) Scarlet Fever. 
Forty cases of scarlet fever were also investigated, 
every alternate case receiving 100 mg. of vitamin C daily 
for eight days. The experiment was discontinued after 
the fortieth case for the following reasons: - 
1. Since the mild type of scarlatina that has been 
prevalent in recent years gives rise to remarkably few 
complications, a very large -scale ( and expensive ) exper- 
-iment would be necessary to determine whether treatment 
with ascorbic acid does anything to reduce the incidence 
of complications; moreover, in any such experiment, it 
would be essential to eliminate such other variables as 
dosage of serum ( if any ) and of sulphonamides ( if any). 
2. Apart from the incidence of complications and 
the duration of the incidental tonsillitis, it is difficult 
to find criteria on which to judge the efficacy of any 
treatment for a self -limiting disease like mild scarlatina. 
3. The findings in respect of the duration of the 
tonsillar inflammation were very similar to the results 
obtained in the experiment on simple tonsillitis. 
No useful purpose would be served by recording details 
regarding the individual cases. The only point that seems 
worth stating is that, in two fairly comparable groups each 
containing 20 patients, the average duration of tonsillar 
inflammation was 7.12 days in the cases treated with vitamin 
C, and 8.21 days in the control, and that ( since the 
standard error of the difference is ± 1.22 ) the difference 
is not significant. 
Conclusions from experiments on tonsillitis and scarlet fever. 
In cases of streptococcal tonsillitis, with or without 
a rash, the duration of tonsillar inflammation was rather 
less in cases treated with ascorbic acid than in controls, 
but the difference was well below the level of significance. 
Since the vitamin C cases appeared to advantage in 
two 
separate series ( tonsillitis cases and scarlet 
fever cases) 
it seems quite likely that the vitamin is of 
some slight 
benefit, but only by a repetition of the experiment 
on a very 
large scale would it be possible to determine 
whether the 
observed differences were significant. * 
(4) / - - - - -- 
* As already mentioned on page 15, Glazebrook 
and Thomson in 
1942 carried out a large -scale experiment and concluded 
that 
administration of vitamin C reduced the duration of tonsillitis. 
69 4 ) _POST- INFLUENz L H ULONIA. 
.6Very alternate case admitted with bronchopneumonia 
following influenza was given vitamin C orally, the dosage 
employed being 200 mg. daily for three days. Apart from 
ascorbic acid, the patients received the same treatment. 




Al 50 Li 
A2 27 F 
AS 35 k 
A4 30 k 
AS 62 F 
A6 30 b: 
A7 38 F 
Bi 51 k 
B2 50 BL 
B3 45 F 
B4 41 lk 
B5 26 ;L 
B6 41 iF 
B7 23 ':; k 
Table XI. 











Day of Day of Day of 
! Compile - 
disease disease isease! -ations. 
on on on 
which ; which which 
patient temp. resp. 
entered fell to rate fell 
hospital, normal: to 24 or 
less. 

























4 - 26 
lO - 23 
7 - 22 
14 - 48 x. 
7 - 22 




8 17 ° 
5 Died on 9th. day of illness. 
5 8 13 - 36 
1 3 5 53+ 
Discharge delayed because of kaolin burn. 
° Left hospital on own responsibility before clinically well. 
+ Discharge delayed because of of ulcer at site of injection 
of sulphapyridine. 
Lack of patients brought the experiment 
to 
before a sufficient number had been investigated. 
the cases studied, small though their number is, 
suggest that any benefits conferred by vitamin 
C 
are not great: 
Vitamin C cases. Controls. 
Average duration of pyrexia 6.33 







n 6.5 " 
n 
Average " of rapid respiration 9.33 
" 10.17 
yn 8.5 " Eedian " " " 
10.5 " 
Average duration of hospitalisatn 27.5 
kediàn " ' " 23.5 
It 32.33 " 
35. ". 





Experiment I -_ Oral administration of vitamin C. 
In Edinburgh City Hospital cases of faucial diphtheria 
are habitually divided by the medical superintendent into 
three groups, - F 1, or mild cases, with scanty membrane and 
practically no toxaemia ( Dosage of antitoxin less than 
16,000 units); F 2, or moderate cases, with membrane covering 
both tonsils, some adenitis, and some toxaemia ( Dosage of 
serum about 16,000 to 30,000 units); and F 3, or severe cases, 
with membrane spreading on to the pillars of the fauces, 
marked adenitis and toxaemia ( Dosage of serum, 50,000 or 
100,000 units). Laryngeal cases are similarly divided into 
L 1, L 2, and L 3, Nasopharyngeal cases into NP 1, NP 2 and 
Np 3, and the same procedure is adopted for the other forms 
of the disease. 
It was felt that a fairer picture of the effects of 
ascorbic acid therapy would be obtained by applying the 
alternate case principle to each of these three classes - 
mild cases, moderate cases, and severe cases - than by 
simply giving vitamin C to every second case of diphtheria 
admitted to hospital. Accordingly, for a period of about 
five months, every alternate admission in each class was 
given ascorbic acid by mouth, the dosage selected being 
100 mg. daily for eight days for patients of eight years or 
over, and 50 mg. daily for eight days for younger children. 
Out of 120 cases admitted to hospital, 116 were originally 
included in the experiment, the four exclusions being 
patients who died within a few hours of admission. 
Subsequent exclusions on bacteriological grounds. 
In 20 of the mild cases and 6 of the moderate cases 
the diagnosis of diphtheria was not confirmed bacteriolog- 
-ically. These 26 cases have therefore been excluded, 
leaving the figures for the various categories as follows: 
kild cases: vitamin C group = 37 - 11 (excluded) 
= 26., 
controls = 37 - 9 ( " ) 
= 28. 
koderate " : vitamin C group = 13 - 6 ( 
It 
) = 7 , 
controls = 13 - 0 ( " 
) = 13. 
Severe cases: vitamin C group = 
8, 
= 8. controls 
The classification of these cases 
into mild, moderate 
and severe was made by the medical 
superintendent; and the 
discharging of the patients was arranged 
by a colleague who 
did not know whether any particular 




Details of the mild cases are given below in tables 
XII and XIII. The moderate and severe cases will be 
considered later. 
Table XII. 




















19 ; M 
20 F 
21 1 M 





Age, Description.' Dosage Durations Complications; 
in ' Of serum of illness and sequelae. 






























F 1 6 
F 1 10 
F 1. 6 
F 1 4 
F 1 4 
F 1 8 
F 1 8 
F 1 8 
F 1 8 
F 1 4 
NF 1 12 
2 1 4 
F 1 8 
F 1 8 
F 1 8 
F 1 4 
F 1 10 
F 1 10 
F 1 6 
F 1 6 
L 1 10 
F 1 8 
F 1 8 
F l 5 
F 1 30 
42 Ciliary paresis. 
29 - 

























Mild cases of diphtheria used as controls. 
No. Sex.;Age Descriptiond Dosage 'Duration; Complications. 
¡ in ¡of serum pf illness 






1 F .14 . 
2 F '19 
3 F 26 : 
4 li 5 
5 F 17 
6 F 17 
7&ï 5 
8 h+': . 3 
9 F 5 
(F & L)1; 10 i 42 
F1! 6 33 
F 1 4 37 
F 1° 8 ; 44 
(F & L)1 4 ; 38 
F 1' 8 40 
F1? 4 33 
F 1 20 i 44 
F 1 8 37 
( Continued on next page.) 




Table XIII (continued). 
Description.; Dosage.! Duration.' Complications. 
10 F 
; 
8 F 1 5 26 - 
11 ! F 126 AN 1 4 19 - 
12 F 139 F 1 6 34 - 
13 F 20 F 1 8 34 - 
14 F 2 F 1 6 35 - 
15 1 7 F 1 5 31 - 
16 i Ivi 3 AN 1 4 28 - 
17 Iv: 20 r' 1 10 54 - 
18 ` F 7 F 1 6 37 - 
19 F 8 F 1 4 26 - 
20 - k 5 F 1 8 44 - 
21 : k 7 F 1 5 32 - 
22 &i 4 F 1 10 37 - 
23 : F 16 F 1 10 37 - 
24 F 23 F 1 4 26 - 
25 
. F 19 F 1 8 40 - 
26 : 14 13 F 1 8 44 - 
27 6 r' 1 8 37 - 
28 t b: 3 F 1 20 44 - 
Comparison of the mild cases. 
The two series of mild cases are comparable in respect 
of age, as the following classification will show: 
Age. Vitamin C cases. Controls. 
Over 20 years. 4 4 
10 - 20 " 9 9 
6 - 9 " 5 6 
4 & 5 " 4 5 
2 & 3 " 4 4 
26 28. 
Although all the cases were mild, there is some dis- 
-parity between the groups in respect of degree of mildness. 
Classification according to the dose of antitoxin prescribed 
by the medical superintendent of the hospital reveals that 
the controls had a larger number of very mild cases: 
Dose of serum. Vitamin C cases. Controls. 
10,000 units or more. 7 6 
8,000 " 9 8 
6,000 " or less. 10 14 
26 28. 
To obviate any possibility of an error arising from 
the preponderance of very mild cases among the controls, 
the comparison between the patients treated with ascorbic 
acid and the patients used as controls will be made in 
three separate groups, - cases that received at least 
10,000 units of antitoxin, cases that received 8,000 units, 
and cases that received not more than 6,000 units. 
Total/ 
Total Complications, Average Tedian 






units. 7 2 
Similar 
controls. 6 0 
40.3 days. 42 days. 









39.9 " 39 " 





or less. 10 0 36.2 " 32 " 
Similar 
controls. 14 0 31.1 " 32.5 " 
There were no fatalities among these 54 cases, and 
complications were far too infrequent to allow of the 
drawing of even tentative conclusions. As for duration 
of illness, it will be observed that, in each comparable 
section, the median duration of stay in hospital is half 
to one day longer in the controls than in the treated cases, 
while the average is longer in the controls of two sections 
but shorter in the controls of the third section. In this 
third section the average for the vitamin C cases is con- 
- siderably distorted by two patients ( No. 17 and No. 20 
in Table XII ), so that the median is probably a truer 
guide. 
For mild diphtheria, then, the results are very 
similar to those found in tonsillitis: the duration of 
illness in the cases treated with ascorbic acid appears to 
be a shade less than the duration in comparable controls, 
but the difference is so slight that it would probably be 
necessary to study several hundreds of cases before one 
could decide whether the difference was significant or due 
to chance. 
Loderate and severe cases. 
Details of the 20 moderate cases and of the 16 severe 




Moderate and severe cases of diphtheria treated with vitamin C. 
No. .Sex.' Age WDescription.! Dosage Duration Complications 











1 li 2 NP 2 30 
2 M 11 F 2 20 
3 M 5 .NP 2 20 
4 M 1 F 2 20 
5 M 3 ( NP,..L ) 2 20 
6 F 3 ï' 2 20 
7 h- 4 F 2 20 
A F 16 NP 3 50 
B F 7 NP 3 50 
C Ni 3 NP 3 130 
D F 9 NP x* 100 
E F 5 NP 3 100 
F Aä 6 NP 3 50 
G F 16 NP 3 100 







Died on 8th. day in hospital. 
94 Heart failure; palatal, 





* A haemorrhagic case which made a complete recovery. 
" x " signifies, " hopeless prognosis ". 
.Table XV. 
Moderate and severe cases of diphtheria used as controls. 
No. Sex.!Age Description.! Dosage Duration Complications 
in lof serum of and sequelae. 
yrs 1 in illness 
thousands days. 
of units. 
1 M 3 (F & L)2 30 56 - 
2 M 5 F 2 16 48 - 
3 F 3 NP 2 16 47 - 
4 F 11 F 2 20 47 - 
5 F 27 (F & L)2 20 58 - 
6 M 3 F2 20 44 - 
7 M 15 NP 2 20 Died on 9th. day in hospital. 
8 k 5 F 2 16 38 Strabismus. 
9 M 3 NP 2 30 54 - 
10 F 14 F 2 16 45 - 
11 F 7 F 2 28 66 - 
12 M 26 NP 2 30 42 - 
13 ! M i 41 NP 2 20 46 - 
A F 1 6 
B F 2 




E Iv: I 4 
F k ; 59 
G F 4 
H F 11 
+ Died / 
NP 3 
I 
100 Died on 7th. day in hospital. 
NP 3 100 Died on 3rd. day " it 
NP 3 50 Died on 3rd. day " II 
NP 3 46 -77 Ciliary paresis. 
NP 3 100 82 Late adenitis. 
(NP &L) 3 50 + 
NP 3 50 Died on 2nd. day in hospital. 
NP 3 100 Died on 9th. " " " 
75 
+ Died. of intercurrent lobar pneumonia on 35th. day of 
diphtheria. 
Compárison of moderate and severe cases. 
As compared with the moderate cases which received 
vitamin C, the moderate controls are older ( five of them 
being older than the oldest child in the treated group ), 
and contain a larger proportion of relatively mild cases: 
four of the thirteen controls required only 16,000 units 
of antitoxin. Hence comparison of the two moderate groups 
has a very limited value. The main points of difference, 
for what they are worth, are as follows; - 
Total Deaths. Sequelae. Average Median 
cases. duration duration 
in days. in days. 
koderate 
vitamin 
C cases 7 0 2 57.7 50 
moderate 
controls 13 1 1 49.3 47 
The two groups of toxic cases are quite well balanced 
in respect of dosage of serum: five treated cases and four 
controls had 100,000 units, while the others received 50,000 
units. They are also fairly comparable in respect of age, 
although the control series contains one elderly adult. 
The main points concerning the severe cases can be 
summarised thus: - 
Total Deaths. Complications Average Median 





C cases 8 
Severe 
controls 8 
1 1 74. days. 70 days 
5° 2 74.5 " 74.5 " 
One cannot, of course, form definite conclusions from 
sixteen severe cases; but the mortality rates ( 12.5 ¡o and 
62.5 o respectively ) and the incidence of complications in 
survivers ( 14.29 ¡o and 66.67 o respectively ) show such 
marked differences as to make a further investigation 
eminently desirable. 
Experiment / 
° The man who died of intercurrent lobar pneumonia is not 
included among the deaths. 
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Experiment II - Parenteral administration of vitamin C. 
As a result of Experiment I the writer felt that mild 
cases did not merit further investigation, but that severe 
cases deserved further study ( in view of the apparently 
beneficial results of ascorbic acid therapy in the small 
number of severe cases previously described), and that the 
second experiment might profitably include moderate cases 
also ( in view of the fact that the moderate groups of 
Experiment I were not really comparable). 
It seemed likely that, if orally administered vitamin 
C - which might or might not be absorbed from the alimentary 
tract - was of value in severe diphtheria, then, a fortiore, 
intravenous injection of the vitamin would be beneficial; 
and conversely, if intravenous ascorbic acid proved to be 
useless, oral treatment with the vitamin would probably be 
useless. Accordingly, the writer decided to give vitamin 
C parenterally, and - in view of the large doses tried by 
some of the German workers ( see Part 1 ) - to use a dosage 
of such magnitude that any negative results could not 
possibly be attributed to inadequacy of amounts given. The 
quantity selected was, for a patient over the age of eight 
years, 500 mg. daily for ten days, and for a younger child 
250 mg. daily for the same period. 
Selection of cases. 
To eliminate errors due to the presence of another 
variable, namely, dosage of antitoxin, it was decided to 
give vitamin C to every second case that received 100,000 
units of serum, to every second case that received 50,000 
units, and to every second case that received 30,000 
units. 
It was originally intended that the 5,000 mg. of 
vitamin C ( or 2,500 mg. for young children ) should be 
given in ten daily intravenous injections. However, as 
some of the patients admitted at the beginning of the 
experiment had very " difficult i' veins, the plan was 
altered: each patient was given intravenous injections 
of 500 mg. or 250 mg. ( according to age ) for three days, 
and intramuscular injections of the same quantities of 
the vitamin for the next seven days. 
In all, eighteen severe cases of diphtheria and 
six moderate cases were investigated. Details of the 
individual patients are recorded in Tables XVI and XVII 




Cases of diphtheria given ascorbic acid parenterally. 
No. Sex. Age Dosage ( Complications 'Duration of 
in of serum or illness in 
yrs. in Secïuelae. ! days. 
thousands 
of units. 
1 Ivi 9 100 ; Palatal paresis. 69 
2 i F 42 100 Died on 10th. day of disease (3rd. day in hosp.) 
3 F 11 100 - 108 
4 li 14 100 - 69 
5 ' k 
6 LI 
7 ' F 
8 ; Ilrí 
9 14í 
s- 
42 50 Strabismus and 70 
Palatal Paresis. 
5 50 - 54 
2 11/12 50 - 74 
21 50 Palatal paresis 63 
10 50 - 85 
10 F 9 30 - 56 
11 liï 2 30 Palatal paresis 86 
12 
i 
Ii 7 30 Palatal paresis 74 
Table XVII. 
Cases of diphtheria used as controls. 
Lo. Sex. Age Dosage Complications Duration of 
in of serum or illness in 





















Died on 12th. day of disease (11th. day in hos,).) 
- 70 
Died on 7th. day of disease (4th. day in hosp.) 
- 95 
5 IV: 14 50 - 70 
6 t, 5 70 *Died on 12th. day of disease (8th. day in hosp.) 
7 F 1 4/12 50 - 73 
8 k 4 50 Palatal and Ciliary pareses, 
Died on 110th. day of disease. 
9 L. , 8 50 - 103 
10 Iti: 6 30 - 60 
11 F 3 30 Strabismus 73 
12 i F ' 2 30 I Strabismus 67 . 
* The 70,000 units in Case 6 includes 20,000 prior to admission. 
It should perhaps be mentioned that the only fatality 
amonG the vitamin C patients - Table XVI, Case No. 2 - was 
a haemorrhagic case. 
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The main points concerning the two groups may be 
tabulated thus:- 
Total Number No. who 
cases. who developed 
died. cornplic- 
-ations. 
a) Patients given 
100,000 units 
of antitoxin. 
Vitamin C cases 4 
Controls 4 
b) Patients given 
50,000 units. 
Vitamin C cases 5 
Controls 5 
c) All severe 
cases. 
Vitamin C cases 9 
Controls 9 
d) koderate cases 
( 30,000 units). 
Vitamin C cases 3 
Controls 3 
e) Total cases. 















1 82. days. 69 days. 





1 3 74. 















1 5 73.5 " 70 
4 ; 4 76.4 " 71.5 " 
The results run roughly parallel with those of the 
first experiment: i.e. in the moderate cases ( those that 
received 30,000 units of serum ) there is little difference 
between the treated patients and the controls, but the toxic 
cases which were given ascorbic acid show a considerable 
lowering of the mortality rate as compared with the controls, 
- 1/9 as against 4/9. 
Consideration of severe cases from both experiments. 
If we now take all the toxic cases from Experiments 
I and II, and divide them into those who received vitamin 
C ( irrespective of whether the vitamin was given orally or 
by injection ) and those who were used as controls, we can 
form two groups, each containing 17 patients. These groups 
are comparable in respect of sex, - for there are nine males 
and eight females in each group; in respect of age, - for 
each contains six children of five years or under, ten older 
children/ 
(y 
children, and one adult; and in respect of dosage of serum, 
- for the vitamin C group comprises nine patients who were 
given 100,000 units and eight who received 50,000 units, 
while the control series contains eight who were given 
100,000 units and nine who received 50,000. koreover, 
since these two series represent a summation of small groups 
to which the alternate case method was invariably applied, 
differences due to changes in the virulence of the organism 
should be minimised. 
In these two well balanced groups there is a very 
marked difference in the mortality rates: the death rate 
among the cases that received vitamin C is 2/11, or 11.76, 
whereas among the controls it is 9/17, or 52.94 ¡0. The 
actual difference in probability of death in the two groups 
is 41.18 ¡,, or 2.86 times the standard error of the differ- 
ence. In other words, the difference is definitely 
significant. 
Comparison of oral and parenteral administration. 
It is never very satisfactory to compare groups of 
patients treated at different times; but, since the death 
rates and complication rates in the toxic control groups 
of the two experiments were not dissimilar ( deaths = 5/8 
and 4/9 respectively, and patients with complications = 
2/8 and 2/9 respectively), it was felt that a comparison 
between the severe cases that received vitamin C orally 
and those that received it by injection might be attempted. 
The eight toxic cases that were given 800 mg. of the 
vitamin by mouth included one that died and one that 
developed various complications, the latter case being a 
haemorrhagic diphtheria which made a complete recovery. 
The nine toxic cases that received 5,000 mg. parenterally 
included one that died ( a haemorrhagic case ) and three 
that developed complications. 
It seemed probable, then, that the very high dosage 
employed in Experiment II was unnecessary, and that paren- 
-teral administration ( which is more laborious and much 
more expensive ) possessed no marked advantage over treat - 
-ment by the oral route. Nevertheless, since diphtheria 
is not infrequently characterised by initial nausea and 
sickness, it was felt that at least the first dose of the 
vitamin might well be given parenterally. 
Accordingly, it was decided that, in the next exper- 
-iment, patients would be given 500 mg. intravenously, and 
thereafter would receive their ascorbic acid by mouth. 
Experiment / 
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Experiment III - Confirmatory. 
Although the two experiments conducted at Edinburgh 
City Hospital had revealed a significant difference between 
the mortality rates of severe cases of diphtheria treated 
with vitamin C and those of severe cases that did not have 
the benefit of such treatment, a further investigation was 
deemed advisable, not so much to corroborate the general 
finding that ascorbic acid was of value, as to confirm the 
decision that the major portion of the vitamin could be 
given orally. Accordingly, at Kendray Isolation Hospital, 
Barnsley, during the winter of 1941 -42, every alternate 
severe case and every alternate moderate case of diphtheria 
was treated with vitamin C, the dosage employed being 
500 mg. intravenously ( irrespective of patient's age ) on 
admission, and 200 mg. or 100 mg. daily ( according to 
whether the patient was over or under the age of eight 
years ) for three days. The control patients received no 
supplement of vitamin C during the first week of their stay 
in hospital. In the second and later weeks all patients 
were given vitamin C orally in small quantities, sufficient 
to raise the ascorbic acid level of war -time diets to the 
more generous standard of normal times. 
Possible fallacies. 
In a small hospital, where cases admitted during the 
morning or afternoon were seen by the writer but where 
evening duty was taken in rotation by four members of the 
staff of the public health department, one could not hope 
to achieve the same standard of uniformity of dosage as is 
obtained in larger institutions; but, while an isolated 
case might receive an amount of serum slightly disproport- 
-ionate to its severity, there is no reason to suppose that 
such occasional slight disproportions would upset the balance 
between the groups of cases. 
A fact more likely to lead to error is that the 
discharging of the patients was in the hands of the writer, 
who might be unconsciously biased by his knowledge of 
whether any particular case had been treated with vitamin 
C. To obviate any fallacy from this cause, "Duration of 
illness" has been omitted from the criteria used in compar- 
ing the groups: treated cases and controls have been 
compared only in respect of incidence of deaths and of 
frequency of complications and sequelae. 
Details of cases. 
The alternate case method was applied to moderate 
cases which received about 40,000 units of antitoxin, and 
to severe cases that were given about 60,000 units. These 
categories correspond with Edinburgh cases receiving 
30,000 units and 50,000 to 100,000 units respectively, the 
dosage/ 
dosage used being generally a shade higher than that 
employed in Edinburgh, because south Yorkshire seems to 
harbour a particularly virulent strain of C. Diphtheriae. 
Details of individual cases are recorded in Tables 
XVIII and XIX. 
Table XVIII. 
Cases of diphtheria treated with vitamin C. 
No. Sex. Age 
in 
yrs. 
Description* Dosage , 




































F 11 F 3 60 - 
F 12 F 3 60 - 
F 4 NP 3 80 Otitis, unilateral. 
F 4 F 3 60 - 
' F 2 F 3 60 - 
F 6 F 3 60 Cardiac failure. 
F 1 10/12 F 3 80 - 
F 11 F 3 60 - 
' 5 F 3 60 Neuritis. 
F 10 NP 3 80 - 
F 10 NP 3 60 - 
LI 8 F 3 60 - 
F 4 L 2 40 
Ii; 9 F 2 40 
IL 14 NP 2 40 
F 16 F 2 40 
F 4 F 2 50 
, F 2 F 2 40 
Sex. 
Table XIX. 
Cases of diphtheria used as controls. 
Age Description* Serum (in Complications, &c. 
in thousands 
yrs. of units.) 
k 13 NP 3 60 Bradycardia. 
F 11 NP 3 60 Palatal paresis; died on 43rd. day. 
F 12 F 3 80 Cardiac failure. 
F 11 F 3 90 Palatal and ciliary paresis. 
F 12 F 3 80 
F 8 NP 3 80 Died on 1st. day in hose. 
M 24 F 3 60 
F 20 F 3 60 
F 18 F 3 60 
M 7 F 3 60 
k 5 F 3 60 
k 2 F 3 60 Cardiac failure. 
F 7 F 2 40 Facial & palatal paresis. 
F 7 F 2 40 
Id 6 F 2 40 
F 9 F 2 50 Cardiac failure. 
F 5 F 2 40 Cardiac failure & strabismus. 
F 14 F 2 40 Palatal paresis. 
* The/ 
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The contractions used in the description of cases - "F 2 ", 
"F 3 ", etc. - have the same significance as in the earlier 
experiments. 
Comparison of the groups. 
There are more young children among the vitamin C 
cases than among the controls, - a fact which should 
certainly not incline the balance in favour of the treated 
cases. In other respects the series are quite comparable. 









No. who had an 
uncomplicated 
convalescence. 
Vitamin C cases 12 0 3 9 
Controls 12 2 5° 6 
b)L oderate 
Vitamin C cases 6 0 0 6 
Controls 6 0 4 2 
c)Total 
Vitamin C cases 18 0 3 15 
Controls 18 2 9° 8 . 
° Including one patient who died later ( and who is therefore 
counted in two separate columns ). 
In these two groups of 18 patients, the difference 
in the probability of recovery without sequelae is 38.89 ¡1;, 
or 2.66 times the standard error; and the difference in 
the probability of death is 1.5 times the standard error. 
Discussion of findings in all three experiments. 
The 150 cases of diphtheria that were investigated 
comprised 54 mild, 38 moderate, and 58 severe cases. From 
these not inconsiderable numbers, it should be possible to 
determine whether ascorbic acid therapy serves any useful 
purpose. 
A drug may be deemed of value in diphtheria if it 
shortens the period of illness, or if it reduces the 
frequency of sequelae and complications, or if it lowers 
the death rate. Let us apply these three criteria to 
treatment with vitamin C. 
(1) Does administration of vitamin C shorten the 
period of illness ? 
In Experiment I it was found that, for three 
separate/ 
83 
separate groups of mild cases, the median duration of 
illness in cases treated with vitamin C was half to one 
day less than the median duration in the controls; and 
in the group of severe cases the median was 4Z days less 
in the treated cases than in the controls. The severe 
cases of Experiment II gave similar results: the median 
length of illness was 3; days shorter in treated patients 
than in controls. There are therefore five groups of 
patients in which the median duration was slightly less 
in the vitamin C cases than in the controls; and in four 
of these five the average duration was also shorter in 
the treated cases, while in the fifth - the mild patients 
who received not more than 6,000 units of antitoxin - the 
average was distorted by two abnormal cases. 
On the other hand, there are two groups - the mod - 
-erate cases of Experiment I and of Experiment II - where 
the average duration and the median duration of illness 
were both longer in the treated cases than in the controls; 
but the moderate cases of Experiment I have been shown to 
be hardly comparable, and the moderate cases of Experiment 
II form an exceedingly small group. 
On balance, the patients treated with ascorbic acid 
were discharged from hospital a little earlier than the 
ones who were not so treated, but the differences are so 
slight that only by a most extensive and prolonged invest- 
- igation would it be possible to determine whether these 
differences were really significant. 
The question, " Does administration of vitamin C 
shorten the period of illness ? ", cannot be answered with 
a definite affirmative. 
(2) Does treatment with the vitamin reduce the incid- 
-ence of complications or of secuelae ? 
In the 150 cases studied, complications - as distinct 
from sequelae - were very infrequent: there were two compl- 
-ications ( one case of otitis and one of late adenitis ) 
among the treated cases, and one ( late adenitis ) among 
the controls. 
The percentage of patients who developed sequelae was 
15.49 in the vitamin C cases, and 18.99 in the controls; 
and the total number of sequelae per hundred patients was 
23.94 in the treated cases and 24.05 in the controls. A 
detailed consideration of the individual sequelae suggests, 
however, that there may be a difference between the vitamin 
C cases and the controls: while post- diphtheritic paralysis 
was equally common in treated and in untreated cases - 14 
instances of paralysis occurred in each category -, there 
was a certain amount of disparity in the incidence of the 
most dangerous of the common sequelae, cardiac failure. 
Out / 
v-t 
Out of 79 controls, five developed non- lethal heart failure 
( to say nothing, for the moment, of the twelve who died ), 
whereas in the 71 cases treated with vitamin C there were - 
apart from the two patients who died - only three cases of 
cardiac failure. 
It can be stated definitely that ascorbic acid therapy 
floes not reduce the frequency of post- diphtheritic paresis. 
Whether it does anything to prevent cardiac ( or circulatory) 
failure will - since this failure is the common cause of 
death in diphtheria and was responsible for all the deaths in 
the observed cases - be shown by the answer to question three. 
(3) Does administration of ascorbic acid lower the death 
rate ? 
A comparison of all the moderate and severe cases that 
received ascorbic acid with all the moderate and severe 
controls would be unfair to the treated patients for two 
reasons, - first, because the moderate controls of Experiment 
I have already been shown to be rather milder than the 
corresponding treated cases; and, second,. because the 
disparity in numbers between the moderate controls of the 
first Experiment and their treated counterparts would cause 
the total group of controls to contain a higher percentage 
of moderate cases than the total group of treated cases. 
Nevertheless, let us make the comparison. 
The moderate and severe cases treated with vitamin C 
consist of 29 toxic cases and 16 moderate cases, - i.e. 45 
in all. The corresponding controls comprise 29 toxic cases 
and 22 moderate cases, - i.e. 51 in all. The mortality 
rate in the treated cases is 2/45, or 4.44 %, while in the 
controls it is 12/51, or 23.53 %. The standard error of 
the difference is ±6.63. Hence the actual difference of 
19.09 % is 2.$5 times the standard error: so, even in this 
weighted comparison, the difference is significant. 
If we disregard the moderate cases ( which included no 
fatalities among treated cases and only one death among the 
controls ), and contrast the 29 toxic cases that received 
vitamin C with the 29 toxic cases that did not have any 
such treatment, we find that the proportion of fatalities 
is 2/29 in the one Group and 11/29 in the other, the actual 
difference being 3.05 times the standard error. 
Even more convincing than these statistical calculations 
is a simple summary of the four groups in which deaths 
occurred:- 
Vitamin C cases. Controls. 
Description. Deaths /Cases. Deaths /Cases. 
Loderate cases, Exp. I 0/7 1/13 
Severe " " I 1/8 5/8 
Severe " " II 1/9 4/9 




Vitamin C cases. Controls. 
Deaths /Cases. Deaths /Cases. 
2/36 12/42. 
Administration of vitamin C, then, definitely lowers 
the mortality rate. 
Dosage and method of administration. 
The purpose of the investigations previously described 
was to determine whether treatment with vitamin C served any 
useful purpose. However, since the treated cases of the 
first experiment received 800 mg. orally, those of the second 
experiment 5,000 mg. parenterally, and those of the last 
experiment 500 mg. intravenously followed by 600 mg. orally, 
it may be possible to form a rough idea of the best route of 
administration and of the minimum adequate dose of the 
vitamin. 
Comparison of groups of patients treated at different 
times and in different places is, of course, never really 
satisfactory. However, a consideration of the various 
control groups suggests that the virulence of the organism 
and the resistance of the host did not vary unduly: 
Group. Total Deaths. Heart failure 
cases. with recovery. 
Toxic controls of Exp. I 8 5 0 
II II 
" " II 9 4 0 
it tt It " III 12 2 3 
Loderate II if " I 13 1 0 
" " t' t' II 3 0 0 
It n tt " III 6 0 2. 
The corresponding figures for the treated cases are: 
Group. Total Deaths. Heart failure 
cases. with recovery. 
Toxic cases of Exp. I 8 1 1 
II tt " " II 9 1 0 
II t' " " III 12 0 1 
Loderate t' t' " I 7 0 1 
" tt " " Il 3 0 0 
" II " " III 6 0 0 . 
Despite the many possible fallacies inherent in a 
comparison of such groups, it may be claimed that the 
exceedingly high dosage of Experiment II is unnecessary: 
the patients of Experiment III made quite as good progress. 
On the other hand, the cases of Experiment I seem to be 
a shade less favourably placed. This may well be due 
to chance, or to the earliest cases investigated having 
happened to be a little more toxic; but, until further 
evidence is available, it is safer to assume that cases 
of Experiment I were given rather less than the optimum 
dosage./ 
dosage. 
It appears, then, that a case of diphtheria will 
receive sufficient ascorbic acid if given 500 mg. intra- 
-venously, followed by 300 to 600 mg. orally, according 
to age. 
Ascorbic acid therm in diphtheria Conclusions. 
It is doubtful whether administration of vitamin C 
to mild cases of diphtheria serves any useful purpose 
other than that of remedying the state of hypovitaminosis 
C, - which state could be just as effectively remedied by 
the provision during convalescence of a diet containing 
abundance of fresh fruit and green vegetables. 
In all severe cases of diphtheria, on the other hand, 
treatment with adequate dosage of vitamin C is eminently 
desirable: such treatment significantly reduces the 
mortality rate. 
SUMMARY AND CONCLUSIONS. 
To ascertain whether the administration of ascorbic 
acid in certain infectious diseases was attended by any 
beneficial results, some 456 patients were investigated 
in Edinburgh City Hospital, and 52 patients in Kendray 
Isolation Hospital, Barnsley, were studied in subsequent 
corroborative experiments. Immediately after admission 
to hospital, cases of each disease were allocated - on 
the alternate case principle - to'one or other of two 
groups. These groups received similar medicaments and 
diet, except that Group I was given synthetic vitamin C. 
The main findings are mentioned in the - following summary. 
1. Influenza. 
108 adult males, admitted during an epidemic of a 
fairly mild type of influenza, were divided into two 
groups, comparison of which revealed no serious discrep- 
-ancy in respect of initial severity, age distribution, 
etc. Members of Group I received 400 mg. of vitamin C 
during their first two days in hospital, while members 
of Group II were used as controls. 




and complications, and a shorter average length of illness, 
the observed differences were not of such magnitude as to 
be statistically significant: the difference in probability 
of recovery without complications was 2.16 times the standard 
error of the difference, and the difference in average dur- 
-ation of illness was only 1.66 times the standard error. 
The dosage of vitamin C used in this experiment was 
selected in the light of Falke's estimates of the amount of 
the vitamin metabolised in pyrexia, but investigation of the 
urinary excretion of patients in Group I suggested that the 
amount of ascorbic acid administered had been insufficient 
to remedy the state of hypovitaminosis C. However, since 
influenza is seldom treated in isolation hospitals, no 
opportunity was found of repeating the experiment with a 
higher dosage of the vitamin. 
2. Cerebrospinal Meningitis. 
(a) Oral administration of the vitamin. 
For 120 consecutive admissions each alternate case 
was offered 600 mg. of ascorbic acid by mouth during the 
first four days in hospital. As some patients were too 
sick to retain the vitamin, a standard of exclusion 
equally applicable to both groups had to be devised, and 
for this purpose ability to tolerate sulphapyridine given 
by mouth was selected ( because retention of the latter 
drug obviously implies ability to retain ascorbic acid ). 
In all, 42 members of Group I and 46 controls from Group 
II were able to take drugs orally. 
There was no real disparity between the groups in 
respect of duration of illness, but at first glance it 
looked as though the vitamin C cases had a materially 
lower death rate and a smaller incidence of complications. 
Scrutiny of the two groups revealed, however, that the 
controls included a disproportionate number of infants and 
elderly persons. Death rates and complication rates were 
therefore standardised, and it was found that, although 
the differences remained in favour of the group treated 
with vitamin C, these differences were fax below the level 
of significance; the difference between the standardised 
death rates was 1.05 times the standard error, whilst that 
between the standardised complication rates was 1.22 times 
the standard error. 
(b) parenteral administration of the vitamin. 
After the oral experiment had been in progress for a 
short time, it was decided that cases excluded from Group 
I ( on the ground of inability to tolerate sulphapyridine 
orally ) should receive 500 mg. of vitamin C intramuscularly, 
while similar exclusions from Group II should be used as 
controls / 
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controls. The injections were given approximately 24 
hours after each patient had been admitted to hospital, 
and they were, of course, additional to any portion of 
the first day's oral dosage that the patient had managed 
to retain. Twelve cases received intramuscular inject - 
-ions of ascorbic acid, and thirteen cases fell into the 
control series. 
Contrary to the investigator's expectation, the 
differences between the two groups were dramatic: in the 
vitamin C cases the death rate was very little more than 
half of the death rate among the controls, while the 
percentage of recoveries without complications was almost 
twice that of the control group. 
In view of these remarkable differences, a further 
trial of parenteral ascorbic acid was judged to be most 
desirable. Accordingly, 30 consecutive cases admitted 
to hospital suffering from meningitis were divided into 
the usual two groups, and the patients in Group I received 
1500 mg. of vitamin C intramuscularly during their first 
three days in hospital ( 500 mg. daily ), whilst members 
of Group II served as controls. Owing to treatment 
being commenced before laboratory reports were to hand, 
two of the Group I cases had to be excluded as pneumococcal, 
not meningococcal. However, the results in the remaining 
cases were sufficiently striking: the 13 cases treated 
with vitamin C included no fatalities and no complications, 
as compared with three deaths and three. complications in 
the control group. Despite the smallness of the numbers, 
the difference in the probability of an uncomplicated 
convalescence was found to be significant. 
The 25 cases that received vitamin C parenterally 
have been compared as a group with the 28 controls; to 
eliminate any possible error due to differences in the 
age distribution, a comparison in age -groups has been made; 
and ( since a study of the controls used at various times 
showed that, during the portion of the epidemic in which 
these experiments were conducted, the disease did not 
undergo any marked change in its severity ) the cases that 
received vitamin C by injection have been compared with 
all the other cases of the disease, - i.e. oral vitamin C 
cases, controls of oral cases, and controls for parenteral 
cases. Every single comparison emphasised the favourable 
position of the cases treated with injections of ascorbic 
acid. 
To " make assurance double sure " a confirmatory 
experiment was carried out at Kendray Hospital, each 
alternate admission receiving 1500 mg. of the vitamin in 
three daily injections. The eight cases in Group I 
included no fatalities and only two with transient complic- 
-ations, as contrasted with one death and four complications 
- three / 
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- three of them lasting - among the eight controls. So 
these cases, although not numerous enough to be significant 
when considered by themselves, corroborate the remarkable 
results of the Edinburgh experiments. 
3. Streptococcal Tonsillitis with or without a rash. 
For a period of eight days, 16 cases of tonsillitis 
due to Str. Pyogenes were given 50 or 100 mg. of ascorbic 
acid each day, orally, while 16 similar cases were used as 
controls. Such differences as were found were in favour 
of the vitamin C cases but were not statistically signif- 
-icant: the average duration of inflammation of the 
tonsils was 1.44 days more in the controls than in the 
treated cases, the standard error of the difference being 
1.34; and the average period of hospitalisation was 1.25 
days longer in the controls, the standard error of the 
difference being ± 1.54. 
Of 40 consecutive cases of scarlet fever every 
alternate case was given ascorbic acid, the dosage used 
being the same as in simple tonsillitis. There was, in 
favour of the treated cases, a slight disparity in the 
average duration of tonsillar inflammation, but it amounted 
to only 1.12 times the standard error of the difference; 
and no other points of difference between the groups were 
noted. 
4. Post -Influenzal Pneumonia. 
Every alternate case admitted with bronchopneumonia 
following influenza received 200 mg. of ascorbic acid by 
mouth each day for three days. Lack of patients brought 
the experiment to a close before an adequate number of 
cases had been investigated. However, consideration of 
the 14 cases studied suggests that vitamin C therapy does 
not produce any marked effects. 
5. Diphtheria. 
(a) Oral administration of vitamin C. 
Cases of diphtheria were classified on admission as 
mild, moderate, and severe cases. In each of these three 
categories every alternate patient was given ascorbic acid 
for eight days, the daily dose being 50 or 100 mg., accord- 
ing to age. 
The 54 mild cases investigated included no fatalities 
and only two with sequelae. The duration of illness was, 
on the average, a shade less in the treated cases than in 
the controls, but the difference was very far below the 
level of significance. The two groups of moderate cases 
- 20 in all - could not legitimately be compared owing to 
disparities in age -distribution and in dosage of antitoxin. 
The / 
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The two groups of severe cases were well balanced in respect 
of dosage of serum, age of patients, etc.; yet the 8 cases 
that received vitamin C included only one fatality, whereas 
the 8 controls included five who died. 
It was therefore felt that, while mild cases needed no 
further study, moderate and severe cases required more inves- 
- tigation. 
(b) Parenteral administration of the vitamin. 
It was decided that, to ensure absorption, the vitamin 
should be given intravenously or intramuscularly, in large 
dosage. To eliminate any errors due to the presence of a 
second variable - namely, amount of antitoxin - the alternate 
case principle was applied to all patients who received 30,000 
units of serum, to all who received 50,000 units, and to all 
who received 100,000 units. Every second case in each of 
these categories was given 2,500 mg. or 5,000 mg. of ascorbic 
acid, according to age, during the first ten days in hospital. 
The twenty -four patients investigated were compared 
class by class. In the 30,000 class there was little dis- 
crepancy between the treated cases and the controls. In 
the other two classes, however, there were marked differences 
in the mortality rates; and when the 50,000 units and 100,000 
units groups were considered together it was found that the 
in probability of death in the severe cases that 
received vitamin C and in the severe controls was 2.66 times 
the standard error of the difference, - i.e. the difference 
was significant. 
After discussion of the relative merits of the small 
oral dose used in Experiment (a) and the very large paxenteral 
dose employed in Experiment (b), a compromise dosage of 500 
mg. intravenously, followed by 300 to 600 mg. orally, was 
suggested. 
(c) Confirmatory experiment. 
In a confirmatory experiment the compromise dosage 
mentioned above was given to every alternate severe case and 
to every alternate moderate case. The twelve severe cases 
that received ascorbic acid included none that died and only 
three that developed complications or sequelae, whereas the 
twelve severe controls included two who died and four who 
suffered from sequelae. In the moderate groups there were 
no deaths, but, whilst the six treated cases recovered without 
any after effects, four of the six controls developed sequelae. 
In a discussion of the entire 150 patients who were 
investigated it has been shown that administration of vitamin 
C significantly lowers the mortality rate, and it has been 
suggested that it acts mainly by reducing the frequency, and 
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the severity, of diphtheritic heart failure. On the other 
hand, treatment with vitamin C does not decrease the incid- 
-ence of post -diphtheritic paralysis. 
Conclusions. 
1. In cerebrospinal meningitis the value of intramuscular 
injections of ascorbic acid is proved beyond shadow of doubt. 
While it is not for a moment suggested that treatment with 
vitamin C should replace sulphapyridine or sulphathiazole 
therapy, the vitamin is a most useful adjuvant: injection 
of 1500 mg. during the first three days of illness causes a 
dramatic drop both in the percentage of deaths and in the 
incidence of complications and sequelae. 
2. Owing to gastro - intestinal upset, oral administration 
of ascorbic acid is often impracticable in cases of cerebro- 
- spinal meningitis; and, even in cases which can tolerate 
drugs given by mouth, it is doubtful whether any real benefit 
is conferred by oral administration of moderate doses of the 
vitamin. 
3. In severe faucial or nasopharyngeal diphtheria treatment 
with adequate amounts of the vitamin significantly reduces 
the mortality rate. An adequate dose for a severe case of 
diphtheria is, - 500 mg. intravenously, with ( or immediately 
after) the antitoxin, followed. by 600 mg. orally during the 
next three days. 
4. Since the dosage just mentioned gives satisfactory 
results in toxic diphtheria, the use of -the parenteral route 
after the first day of treatment appears to be unnecessary 
and - in view of the relative costs of tablets and sterile 
ampoules - undesirable. 
5. In mild diphtheria, streptococcal tonsillitis, and 
scarlet fever oral administration of the vitamin does not 
produce very marked results: such effects as are occasioned 
by ascorbic acid therapy are certainly in the direction of 
shortening the period of illness and the duration of faucial 
inflammation, but the benefits are so trivial that it is 
doubtful whether the giving of synthetic ascorbic acid in 
these diseases is a justifiable expense. It seems probable 
that, under the conditions of normal times, all that is 
necessary is the provision of sufficient fruit drinks during 
the acute stage and of ample fresh fruit and green vegetables 
during convalescence. 
6. In cases of influenza a study of the urinary excretion 
of ascorbic acid proves that 400 mg. of the vitamin ( or 
Falke's suggested dosage of 100 mg. for each day of pyrexia ) 
is insufficient to remedy the state of hypovitaminosis C. 
Since / 
92 
Since treatment with even this inadequate dosage has been 
found, in a comparison of only fifty -four treated and fifty- 
-four untreated cases, to cause a diminution in the incidence 
of complications and relapses sufficiently marked to approach 
the level of statistical significance, it is suggested that 
- until some subsequent investigator definitely proves or 
disproves the value of ascorbic acid in influenza - cases of 
that disease should be given about 200 mg. of the vitamin 
daily for the first three days of illness. 
In brief, then, parenteral administration of vitamin 
C should form part of the treatment of cerebrospinal mening- 
-itis, the drug should be given orally and intravenously in 
severe diphtheria, and it is probably desirable to give the 
vitamin orally to cases of influenza; but in mild diphtheria, 
scarlet fever and tonsillitis the provision of synthetic 
ascorbic acid appears to be an unjustifiable expense. 
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